WO2017133942A1 - Procédé d'hydrogénation catalytique pour la préparation de pyrazoles - Google Patents

Procédé d'hydrogénation catalytique pour la préparation de pyrazoles Download PDF

Info

Publication number
WO2017133942A1
WO2017133942A1 PCT/EP2017/051524 EP2017051524W WO2017133942A1 WO 2017133942 A1 WO2017133942 A1 WO 2017133942A1 EP 2017051524 W EP2017051524 W EP 2017051524W WO 2017133942 A1 WO2017133942 A1 WO 2017133942A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cio
substituted
formula
unsubstituted
Prior art date
Application number
PCT/EP2017/051524
Other languages
English (en)
Inventor
Eric George KLAUBER
Michael Rack
Sebastian Soergel
Birgit GOCKEL
Roland Goetz
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3010561A priority Critical patent/CA3010561C/fr
Priority to AU2017216082A priority patent/AU2017216082B2/en
Priority to RU2018130339A priority patent/RU2733958C2/ru
Priority to KR1020187025347A priority patent/KR102651666B1/ko
Priority to CN201780009304.6A priority patent/CN108699003B/zh
Priority to JP2018558485A priority patent/JP6900400B2/ja
Priority to DK17701485.9T priority patent/DK3411360T3/da
Priority to ES17701485T priority patent/ES2795874T3/es
Application filed by Basf Se filed Critical Basf Se
Priority to MX2018009453A priority patent/MX2018009453A/es
Priority to PL17701485T priority patent/PL3411360T3/pl
Priority to US16/074,537 priority patent/US10975036B2/en
Priority to BR112018014357A priority patent/BR112018014357B8/pt
Priority to EP17701485.9A priority patent/EP3411360B1/fr
Publication of WO2017133942A1 publication Critical patent/WO2017133942A1/fr
Priority to IL260375A priority patent/IL260375B/en
Priority to CONC2018/0008428A priority patent/CO2018008428A2/es
Priority to ZA201805742A priority patent/ZA201805742B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/42—Platinum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/16—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of hydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a catalytic process for preparing pyrazoles comprising the step of cyclizing hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compounds by reacting them with hydrogen in a reaction mixture comprising as components (a) a hydrogenation catalyst, (b) an acid selected from Bransted acids, ammonium salts of Bransted acids, and Lewis acids, (c) a protic solvent, and optionally (d) an aprotic solvent.
  • the present invention also covers the preparation of hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compounds.
  • the preparation of pyrazoles may thus be performed according to the following reaction sequence:
  • the present invention particularly relates to the final step of cyclizing the hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compounds of formula IV (also referred to as pyrazole precursors IV) under the above mentioned reaction conditions to provide the desired pyrazole compounds of formula V.
  • Pyrazole compounds in particular 4-pyrazole carboxylic acid derivatives, such as esters, ni- triles, acids and activated acid derivatives, are versatile intermediate compounds for the preparation of pyrazole derived fine chemicals, such as compounds in the pharmaceutical or agro- chemical field.
  • the compounds are versatile intermediate compounds for the prepa- ration of pyrazole derived pesticides, such as 4-pyrazole N-(het)arylamide compounds, which are known to be particularly useful for combating invertebrate pests (see WO 2009/027393, WO 2010/034737, WO 2010/034738, and WO 2010/1 12177).
  • pyrazole compounds and 4-pyrazole carboxylic acid derivatives which are substituted at one nitrogen atom and optionally also substituted in the 3- and/or 5-position because also the pyrazole de- rived pesticides including the above mentioned 4-pyrazole amide compounds often comprise pyrazole moieties, which are substituted accordingly.
  • the positions of the substituents are indicated by the same numbers.
  • the substituent at the nitrogen atom is typically referred to as the N-substituent rather than as substituent in the 1 -position, although this is also suitable.
  • the 2-position i.e. the second nitrogen atom of the N-sub- stituted pyrazole compounds, is typically unsubstituted.
  • the 3-, 4- and 5- positions may each be substituted.
  • N-substituted pyrazole compounds there is a need for processes for the preparation of N-substituted pyrazole compounds.
  • a particular problem accompanying the preparation of N-substituted pyrazole compounds is the regioselectivity, if substituents are present in the 3- and/or 5-position of the pyrazole ring, in particular, if a substituent is present in the 3-position, but not in the 5-position, if a substituent is present in the 5-position, but not in the 3-position, or if different substituents are present in the 3- and 5-position.
  • N-substituted 4-pyrazole carboxylic acid derivatives can be prepared by reacting an ⁇ , ⁇ -unsaturated carbonyl compound, e.g. an ⁇ , ⁇ -unsaturated ketone, which contains a leav- ing group in the ⁇ -position, with a hydrazine derivative, which has a substituent at one of the two nitrogen atoms.
  • an ⁇ , ⁇ -unsaturated carbonyl compound e.g. an ⁇ , ⁇ -unsaturated ketone, which contains a leav- ing group in the ⁇ -position
  • the substituted hydrazine derivative comprises two amino groups, which are often very similar in terms of their nucleophilic reactivity, two regioiso- mers of the desired N-substituted pyrazole compound are usually obtained because either the substituted nitrogen atom or the unsubstituted nitrogen atom of the hydrazine derivative may re- act.
  • N-substituted 4-pyrazole carboxylic acid derivatives which are 3- and/or 5-substituted, can be prepared by reacting an ⁇ , ⁇ -unsaturated carbonyl compound, e.g. an ⁇ , ⁇ -unsatu- rated ketone, which contains a leaving group in the ⁇ -position, with hydrazine and then N-alkyl- ating the resulting pyrazole derivative. Due to the tautomerism of the pyrazole compound, which is obtained as an intermediate, two regioisomers of the desired N-substituted pyrazole compound are usually obtained upon alkylation. Such reaction sequences have, e.g., been described in Heterocycles 2000, 2775, Liebigs Analen der Chemie 1985, 794, or Journal of Heterocyclic Chemistry 1985, 1 109.
  • a process for regioselectively preparing certain N-substituted 4-pyrazole carboxylic acid derivatives, which are 3-substituted, but not 5-substituted, is known from EP 2671873. Said process is performed by comprising cyclizing a hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compound under UV light irradiation.
  • the process regioselectively provides certain N-substituted 4-pyrazole carboxylic acid derivatives, which are only 3-substituted
  • the process is disadvantageous in that the process works only for certain N- and 3- substituents, and the imino group of the hydrazone is split off by cyclisation, so that the process produces equimolar waste material.
  • N-substituted 4-pyrazole carboxylic acid derivatives which are 3-substituted or 3- and 5-substituted with different substituents
  • the process is disadvantageous in that an excess of at least three equivalents of the nitrile compound has to be used, so that the process is not economical.
  • the process has not been described for HCN as nitrile compound, most likely for the reason that HCN would polymerize under the reaction conditions, so that a cyclization reaction with the enamine compound according to the above reaction scheme would not take place.
  • N-substituted 4-pyra- zole carboxylic acid derivatives which are 5-substituted, but not 3-substituted, can obviously not be obtained according to the process described by Glorius et al.
  • pyrazoles may be prepared by cyclizing hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compounds by reacting them with a certain reagent, for example a reducing agent.
  • said reagent is preferably sodium cyanoborohydride, which is reacted with the hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compounds in the presence of acetic acid to provide the desired razole compounds.
  • the process can be performed as a one-pot procedure, wherein the pyrazole precursor is prepared and then converted into the pyrazole compound without previous purification.
  • the present invention relates to a process for preparing a pyrazole compound of formula V, or a salt, stereoisomer, tautomer or N-oxide thereof
  • R 1 is selected from H, halogen, CN, NO2, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, wherei the aliphatic groups are unsubstituted, partially or fully halogenated, or substituted by one or more identical or different substituents R x ;
  • R 2 is selected from H, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, wherein the aliphatic
  • R 3 is selected from H, halogen, CN, NO2, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, wherein the aliphatic groups are unsubstituted, partially or fully halogenated, or substituted by one or more identical or different substituents R x ;
  • R 4 and R 5 are independently of each other selected from H, NO2, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, wherein the aliphatic groups are unsubstituted, partially or fully halogenated, or substituted by one or more identical or different substituents R x ;
  • Ci-Cio-haloalkyl Ci-C4-alkoxy-Ci-Cio-alkyl, wherein the groups are unsubstituted, or substituted by one or more identical or different substituents Ry;
  • heterocyclyl C3-Cio-cycloalkyl, C3-Cio-cycloalkenyl, hetaryl, aryl, heterocyclyl-Ci-Cs-alkyl, C3-Cio-cycloalkyl-Ci-C5-alkyl, C3-Cio-cycloalkenyl-Ci-C5-alkyl, hetaryl-Ci-Cs-alkyl, aryl-Ci- C5-alkyl, wherein the cyclic moieties are unsubstituted or substituted by one or more identical or different substituents Ry;
  • D is a direct bond, Ci-C6-alkylene, C2-C6-alkenylene, or C2-C6-alkynylene, which carbon chains are unsubstituted or substituted by one or more identical or different substituents R n , and
  • E is a non-aromatic 3- to 12-membered carbo- or heterocycle, which heterocycles contains one or more heteroatoms selected from N-R', O, and S, wherein S is oxidized or non-oxidized, and wherein the carbo- or heterocycle is substituted by one or more identical or different substituents R n ;
  • A is Ci-C6-alkylene, C2-C6-alkenylene and C2-C6-alkynylene, wherein the aliphatic groups are unsubstituted or substituted by one or more identical or different substituents
  • G is Ci-C4-haloalkyl or C3-C6-cycloalkyl, which groups are unsubstituted or substituted by halogen; or
  • R 4 and R 5 together with the carbon atom to which they are attached form a 3- to 12-membered non-aromatic carbo- or heterocycle, which heterocycle contains one or more heteroatoms selected from N-R', O, and S, wherein S oxidized or non-oxidized, and wherein the carbo- or heterocycle is substituted by one or more identical or different substituents Ri;
  • R a , R b are independently of each other selected from H, Ci-C4-alkyl, Ci-C4-haloalkyl, C3-C6- cycloalkyl, C3-C6-cycloalkylmethyl, C3-C6-halocycloalkyl, C3-C6-cycloalkenyl, C3-C6-cyclo- alkenylmethyl, C3-C6-halocycloalkenyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, Ci-C4-alkoxy-Ci-C4-alkyl, heterocyclyl, heterocyclyl-Ci-C4-alkyl, aryl, hetaryl, aryl-Ci-C4- alkyl and hetaryl-Ci-C4-alkyl, wherein the cyclic moieties are unsubstituted or substituted by one or
  • R c is selected from H, Ci-Cio-alkyl, Ci-Cio-haloalkyl, C3-Cio-cycloalkyl, C3-Cio-cycloalkylme- thyl, C3-Cio-halocycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloalkenylmethyl, C3-C6-halocyclo- alkenyl, C2-Cio-alkenyl, C2-Cio-haloalkenyl, C2-C4-alkynyl, Ci-C4-alkoxy-CrC4-alkyl, heterocyclyl, heterocyclyl-Ci-C4-alkyl, aryl, hetaryl, aryl-Ci-C4-alkyl and hetaryl-Ci-C4-alkyl, wherein the cyclic moieties are unsubstituted or substituted by one
  • R c together with the C(Y)0 group forms a salt [C(Y)0]-NR 4 + , [C(Y)0]-M a + or [C(Y)0]-1 ⁇ 2M ea 2+ , wherein M a is an alkali metal and M ea is an alkaline earth metal, and wherein the substituents R at the nitrogen atom are independently of each other selected from H, Ci-Cio-alkyl, phenyl, and phenyl-Ci-C4-alkyl;
  • R d is selected from Ci-C4-alkoxy, Ci-C4-alkyl, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cyclo- alkylmethyl, C3-C6-halocycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloalkenylmethyl, C3-C6- halocycloalkenyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, Ci-C4-alkoxy-Ci-C4-al- kyl, heterocyclyl, heterocyclyl-Ci-C4-alkyl, aryl, hetaryl, aryl-Ci-C4-alkyl and hetaryl-Ci-C4- alkyl, wherein the cyclic moieties are unsubstituted or substituted by one or
  • Ci-C4-alkoxy and Ci-C4-haloalkoxy;
  • R e , R f are independently of each other selected from H, Ci-C4-alkyl, Ci-C4-haloalkyl, C 3 -C6-cy- cloalkyl, C3-C6-cycloalkylmethyl, C3-C6-halocycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloal- kenylmethyl, C3-C6-halocycloalkenyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, Ci- C4-alkoxy-Ci-C4-alkyl, Ci-C4-alkylcarbonyl, Ci-C4-haloalkylcarbonyl, Ci-C4-alkylsulfonyl,
  • R e and R f together with the N atom to which they are bonded form a 5- or 6-membered, saturated or unsaturated heterocycle, which may contain a further heteroatom selected from O, S and N as a ring member atom, and wherein the heterocycle is unsubstituted or substituted by one or more identical or different substituents selected from halogen, CN, C(0)NH 2 , N0 2 , Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxy, and Ci-C 4 -haloalkoxy;
  • R9, R h are independently of each other selected from H, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C3-C6- cycloalkyl, C3-C6-halocycloalkyl, C3-C6-cycloalkenyl, C3-C6-halocycloalkenyl, C2-C 4 -alke- nyl, C2-C 4 -haloalkenyl, C2-C 4 -alkynyl, Ci-C 4 -alkoxy-Ci-C 4 -alkyl, heterocyclyl, heterocyclyl- CrC 4 -alkyl, aryl, hetaryl, aryl-Ci-C 4 -alkyl and hetaryl-Ci-C 4 -alkyl, wherein the cyclic moieties are unsubstituted or substituted by one or more, identical or different substituents selected from halogen, CN, C(0)
  • R' is selected from H, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkylmethyl, C3-C6-halocycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloalkenylmethyl, C3-C6-halocycloal- kenyl, C2-C 4 -alkenyl, C2-C 4 -haloalkenyl, C2-C 4 -alkynyl, Ci-C 4 -alkoxy-Ci-C 4 -alkyl, aryl, and aryl-Ci-C 4 -alkyl, wherein the aryl ring is unsubstituted or substituted by one or more identi- cal or different substituents selected from halogen, CN, C(0)NH 2 , NO2, Ci-C 4 -alkyl, C1-C4
  • R j is halogen, OH, CN, C(0)NH 2 , N0 2 , Ci-Cio-alkyl, Ci-Cio-haloalkyl, Ci-Cio-alkoxy, C1-C10- haloalkoxy, benzyloxy, S(0) m R k , C3-C6-cycloalkyl, or a 3- to 6-membered heterocycle, which contains one or more heteroatoms selected from N-R', O, and S, wherein S is oxi- dized or non-oxidized, which R j groups are unsubstituted or substituted by one or more identical or different substituents R m , and wherein two groups R j connected to the same or adjacent ring atoms may together form a 3- to 6-membered carbo- or heterocycle, which heterocycle contains one or more heteroatoms selected from N-R', O, and S, wherein S is oxidized or non-oxidized, and wherein the cyclic
  • R k is H, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, or C3-C6-cycloalkyl, wherein the cyclic group is unsubstituted or substituted by one or more identical or different substituents R';
  • R' is H, halogen, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkylcarbonyl, or Ci-C 4 -alkoxycarbonyl;
  • R m is halogen, OH, CN, C(0)NH 2 , N0 2 , Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C1-C4- alkoxy, Ci-C 4 -haloalkoxy, or S(0) m R k ;
  • R n is halogen, CN, C(Y)OR c , C(0)NH 2 , N0 2 , Ci-C 2 -alkyl, C C 4 -haloalkyl, C 2 -C 6 -alkenyl, C 2 - C6-alkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkenyl, Ci-C 4 -alkoxy, CrC 4 -haloalkoxy, C1-C4- alkoxy-Ci-C 4 -alkyl, Ci-C 4 -alkyliden, or S(0) m R°; or
  • R° is H, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, or Ci-C 4 -alkoxy;
  • R p is halogen, CN, C(0)NH 2 , N0 2 , Ci-C 2 -alkyl, C C 2 -haloalkyl, C 3 -C 6 -cycloalkyl, C C 4 - alkoxy, or Ci-C2-haloalkoxy; or two groups RP together form a 3- to 6-membered carbo- or heterocyclic ring, which hetero- cycle contains one or more heteroatoms selected from N-R 1 , O, and S, wherein S is oxidized or non-oxidized, and wherein the cyclic groups are unsubstituted or substituted by one or more identical or different substituents R ⁇ ;
  • Rq is halogen, CN, C(0)NH 2 , N0 2 , Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, Ci-C 4 - alkoxy, or Ci-C 4 -haloalkoxy;
  • R x is halogen, CN, C(Y)OR c , C(Y)NR9R h , N0 2 , d-C 4 -alkyl, Ci-C 4 -haloalkyl, C C 4 -alkoxy, d- C 4 -haloalkoxy, S(0) m R d , S(0) m NR e R f , CrC 5 -alkylen-NHC(0)OR c , Ci-Cio-alkylcarbonyl, Ci-C 4 -haloalkylcarbonyl, Ci-C 4 -alkoxycarbonyl, Ci-C 4 -haloalkoxycarbonyl, C3-C6-cycloal- kyl, 5- to 7-membered heterocyclyl, 5- or 6-membered hetaryl, aryl, C3-C6-cycloalkoxy, 3- to 6-membered heterocyclyloxy, or aryloxy, wherein the cycl
  • Ry is halogen, CN, C(Y)OR c , C(Y)NR 9 R h , N0 2 , Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxy, Ci- C 4 -haloalkoxy, benzyloxymethyl, S(0) m R d , S(0) m NR e R f , Ci-C 4 -alkylcarbonyl, Ci-C 4 -haloal- kylcarbonyl, Ci-C 4 -alkoxycarbonyl, Ci-C 4 -haloalkoxycarbonyl, C 3 -C6-cycloalkyl, C 3 -C6-hal- ocycloalkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -haloalkenyl, C 2 -C 4 -alkynyl, or Ci-C 4 -alkoxy-CrC 4 -
  • the process as defined above is suitable for providing a variety of N-substituted pyrazole compounds V.
  • the process also provides the desired pyrazole compounds V regioselectively, which is particularly relevant, if the pyrazole compounds V are 3- or 5-substituted or substituted with different substituents in the 3- and 5-position. Regioselectivity is possible due to the fact that the positions of the substituents are already predefined in the pyrazole precursors IV, which are then cy- clized to give the pyrazole compounds V.
  • the process is also cost-effective and suitable for large scale applications in view of the fact that the cyclization reaction can be performed catalytically with hydrogen as a cheap reducing agent.
  • the process of the present invention provides for the advantage that the cyclization of pyrazole precursors IV regioselectively provides the desired N-substituted pyrazole compounds V with hydrogen as a cheap reducing agent and a catalyst system, which suppresses undesired side reactions to an extent that high yields of the desired N-substituted pyrazole compounds V can be obtained.
  • the pyrazole precursors IV can be obtained from readily and cheaply available starting materials.
  • the pyrazole precursors IV may be obtained by reacting a hydrazone compound II (the compound II itself being obtainable by reacting a suitable carbonyl compound I with hydrazine), with an ⁇ , ⁇ -unsatura- ted carbonyl compound of formula III.
  • certain preferred embodiments of the invention relate to a process, wherein the hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compound of formula IV
  • X is halogen, OH, Ci-Cio-alkoxy, C3-Cio-cycloalkoxy, Ci-Cio-alkyl-C(0)0-, Ci-Cio-alkyl- S(0) 2 0-, Ci-Cio-haloalkyl-S(0) 2 0-, phenyl-S(0) 2 0-, tolyl-S(0) 2 0-, (Ci-Cio-al- kyloxy) 2 P(0)0-, Ci-Cio-alkylthio, C 3 -Cio-cycloalkylthio, Ci-Cio-alkyl-C(0)S-, NH 2 , C1-C10- alkylamino, Ci-Cio-dialkylamino, morpholino, N-methylpiperazino, or aza-C 3 -Cio-cycloal- kyl; and is preferably OCH 2 CH3;
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined above.
  • certain more preferred embodiments of the invention relate to a process, wherein the above hydrazone compound of formula II is prepared by reacting a carbonyl compound of formula I
  • R 4 and R 5 are as defined above.
  • R is C(0)OCH 2 CH 3 ;
  • R 2 is CH 3 ;
  • R 3 is H;
  • R 4 is CH(CH 3 ) 2 ; and
  • R 5 is CH 3 .
  • the present invention therefore also relates to a composition
  • a composition comprising
  • R is C(0)OCH 2 CH 3 ;
  • R 2 is CH 3 ;
  • R 3 is H;
  • R 4 is CH(CH 3 ) 2 ; and
  • R 5 is CH 3 ;
  • the pyrazole compounds V which are prepared according to the process of the present invention, preferably comprise a substituent R 1 , which is suitable for further coupling reactions, in particular amidation reactions.
  • the pyrazole compounds V are selected from pyrazole compounds Va, Vb, or Vc as depicted below, wherein R 2 , R 3 , R 4 , and R 5 are as defined above, and wherein R c in formula Va is Ci-C4-alkyl or aryl-Ci-C4-alkyl.
  • Certain preferred embodiments of the invention relate to a process, wherein the compound of formula V is a compound of formula Va or Vb, and wherein said compound of formula Va or Vb is in a further reaction step converted into a compound of formula Vc, wherein R 2 , R 3 , R 4 and R 5 are as defined above, and wherein R c in formula Va is Ci-C4-alkyl or aryl-Ci-C4-alkyl.
  • certain preferred embodiments of the invention relate to a process, wherein the compound of formula Vc is in a further d into a compound of formula VI
  • X 1 is a leaving group, preferably a leaving group selected from active esters, azide and halogens, particularly preferably p-nitrophenoxy, pentafluorophenoxy or CI, and wherein R 2 , R 3 , R 4 , and R 5 are as defined above.
  • certain preferred embodiments of the invention relate to a process, wherein the above compound of formula VI is in a further reaction step converted into a compound of formula VIII
  • R 2 , R 3 , R 4 , and R 5 are as defined above, and wherein
  • R P1 , R P2 , R P3 , and R u are independently of each other selected from H , halogen, Ci-C4-alkyl, Ci-C3-haloalkyl, Ci-C4-alkoxy, Ci-C3-haloalkoxy, Ci-C4-alkylthio, Ci-C3-haloalkylthio, Ci- C4-alkylsulfinyl, Ci-C3-haloalkylsulfinyl, Ci-C4-alkylsulfonyl, Ci-C3-haloalkylsulfonyl, C3-C6- cycloalkyl, C3-C6-halocycloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl and Ci- C4-alkoxy-Ci-C4-alkyl; and
  • R 1 N is H, CN, Ci-Cio-alkyl, Ci-Cio-haloalkyl, C 3 -Cio-cycloalkyl, C 3 -Cio-halocycloalkyl, C1-C4- alkoxy-Ci-C4-alkyl, C2-Cio-alkenyl, C2-Cio-haloalkenyl, C2-Cio-alkynyl, C3-Cio-haloalkynyl, d-Cs-alkylen-CN, OR a , Ci-C 5 -alkylen-OR a , C(Y)R b , Ci-C 5 -alkylen-C(Y)R b , C(Y)OR c , Ci- C 5 -alkylen-C(Y)OR c , S(0) 2 R d , NR e R f , Ci-C 5 -alkylen-NR
  • U is N or CH; R P1 , R P2 , R P3 are H ; and R 1 N is H, Ci-C 2 -alkyl or C1-C2- alkoxy-Ci-C2-alkyl.
  • pyrazole compounds Va, Vb, and Vc may be further converted according to the following reaction sequence:
  • the compounds of formula IV of the invention may also be referred to as ⁇ , ⁇ - unsaturated carbonyl compounds of formula IV or as pyrazole precursors IV or precursors IV.
  • the compounds of formula V may be referred to as pyrazole compounds V or py- razoles V.
  • N-oxides of the compounds of the present invention can only be obtained, if the compounds contain a nitrogen atom, which may be oxidized. This is principally the case for the compounds of formulae II, IV, V, Va, Vb, Vc, VI, VII and VIII, but not necessarily the case for compounds of formulae I and III. Accordingly, the term "compound(s) according to the invention” will only cover stereoisomers, salts and tautomers of the compounds of formulae I and III, if these compounds do not contain a nitrogen substituent, which would allow for the formation of an N-oxide.
  • N-oxides may principally be prepared by standard methods, e.g. by the method described in Journal of Organometallic Chemistry 1989, 370, 17-31 .
  • the intermediate compounds I, II, III and IV in the preparation of the compounds of formula V are not present in the form of the N-oxides.
  • the compounds are not present in the form of N-oxides.
  • N-oxides are formed at least intermediary.
  • Stereoisomers of the compounds of formulae I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII will be present, if the compounds contain one or more centers of chirality in the substituents. In this case, the compounds will be present in the form of different enantiomers or diastereomers, if more than one center of chirality is present.
  • the compounds of the present invention cover every possible stereoisomer, i.e. single enantiomers or diastereomers, as well as mixtures thereof.
  • a center of chirality is also present in the generic formula, if the substituents R 4 and R 5 are different from H and different from each other.
  • Geometric isomers of the compounds of the present invention are usually possible, if the compounds contain at least one carbon-carbon or carbon-nitrogen double bond because E- and Z- isomers of the compounds may then be present.
  • the compounds of the present invention cover every possible geometric isomer, i.e. single E- or Z-isomers as well as mixtures thereof.
  • a carbon-carbon double bond and/or a carbon-nitrogen double bond is already present in the generic formula.
  • Tautomers of the compounds of formulae I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII include keto-enol tautomers, imine-enamine tautomers, amide-imidic acid tautomers and the like. Such tautomerism is possible, e.g., for the generic formulae I, II, III, IV and VIII (if R 1N is H). Depending on the substituents, which are defined for the compounds of formulae I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII, further tautomers may be formed.
  • the compounds of the present invention cover every possible tautomer.
  • the compounds of formulae I, II, III, IV, V, Va, Vb, Vc, VI, VII and VIII may be present in the form of salts.
  • Such salts will typically be obtained by reacting the compound with an acid, if the compound has a basic functionality such as an amine, or by reacting the compound with a base, if the compound as an acidic functionality such as a carboxylic acid group.
  • the compounds of formula Vb include 4-pyrazole carboxylic acid salts, wherein the cation stems from the base, with which the 4-pyrazole carboxylic acid has been reacted to give an anionic carboxylate.
  • a carboxylic acid group COOH is present in the form of a carboxylate, said anion may be referred to as [C(0)0]-, wherein the negative charge is typically delocalized over the two oxygen atoms of the carboxylate group.
  • the cationic charge of an ammonium cation which may be formed from an amino group in the presence of an acid, is typically not delocalized.
  • Cations which stem from a base, with which the compounds of the present invention are re- acted, are e.g. alkali metal cations M a + , alkaline earth metal cations M ea 2+ or ammonium cations NR 4 + , wherein the alkali metals are preferably sodium, potassium or lithium and the alkaline earth metal cations are preferably magnesium or calcium, and wherein the substituents R of the ammonium cation NR 4 + are preferably independently selected from H, Ci-Cio-alkyl, phenyl and phenyl-Ci-C2-alkyl.
  • Anions which stem from an acid, with which the compounds of the present invention have been reacted, are e.g. chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphos- phate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hex- afluorophosphate, benzoate, and the anions of Ci-C 4 -alkanoic acids, preferably formate, acetate, propionate and butyrate.
  • the compounds of the invention may be in the form of solids or liquids. If the compounds are present as solids, the compounds may be amorphous or may exist in one or more different crystalline forms.
  • the compounds of the present invention cover mixtures of different crystalline forms of the respective compounds as well as amorphous or crystalline salts thereof.
  • the organic moieties mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members.
  • the prefix C n -C m indicates in each case the possible number of carbon atoms in the group.
  • halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine or bromine.
  • alkyl as used herein and in the alkyl moieties of alkylamino, alkylcarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl and alkoxyalkyl denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms.
  • Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1 -methyl- butyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1 ,1 -dimethylpro- pyl, 1 ,2-dimethylpropyl, 1 -methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 , 1 -dimethyl butyl , 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dime- thylbutyl, 1 -ethylbutyl, 2-eth
  • haloalkyl as used herein and in the haloalkyl moieties of haloalkylcarbonyl, haloal- koxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloalkoxy and haloalkoxyalkyl, denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms.
  • Preferred haloalkyl moieties are selected from Ci-C4-haloalkyl, more preferably from Ci-C3-haloalkyl or Ci-C2-haloalkyl, in particular from Ci-C2-fluoroalkyl such as fluoromethyl, difluoromethyl, trifluo- romethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2, 2-trif I u oroethy I , pentafluoroethyl, and the like.
  • alkoxy denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms.
  • alkoxy group examples are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert.-butyloxy, and the like.
  • alkoxyalkyl refers to alkyl usually comprising 1 to 10, frequently 1 to 4, preferably 1 to 2 carbon atoms, wherein 1 carbon atom is substituted by an alkoxy radical usually comprising 1 to 4, preferably 1 or 2 carbon atoms as defined above. Examples are CH2OCH3, CH2-OC2H5, 2-(methoxy)ethyl, and 2-(ethoxy)ethyl.
  • haloalkoxy denotes in each case a straight-chain or branched alkoxy group having from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms.
  • Preferred haloalkoxy moieties include C1-C4- haloalkoxy, in particular Ci-C2-fluoroalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoro- methoxy, 1 -fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-flu- oroethoxy, 2-chloro-2,2-difluoro-ethoxy, 2,2-dichloro-2-fluorethoxy, 2,2,2-trichloroethoxy, pen- tafluoroethoxy and the like.
  • Ci-C2-fluoroalkoxy such as fluoromethoxy, difluoromethoxy, trifluoro- methoxy, 1 -fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2
  • alkylthio (alkylsulfanyl: alkyl-S-)
  • alkyl-S- alkylthio
  • haloalkylthio refers to an alkylthio group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.
  • haloalkylsulfinyl refers to an alkylsulfinyl group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.
  • haloalkylsulfonyl refers to an alkylsulfonyl group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.
  • haloalkylcarbonyl refers to an alkylcarbonyl group as mentioned above, wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.
  • alkoxycarbonyl refers to an alkylcarbonyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • haloalkoxycarbonyl refers to an alkoxycarbonyl group as mentioned above, wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.
  • alkenyl denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. vinyl, allyl (2- propen-1 -yl), 1-propen-1-yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1 -yl), 2-buten-1-yl, 3- buten-1 -yl, 2-penten-1-yl, 3-penten-1 -yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en- 1 -yl and the like.
  • haloalkenyl refers to an alkenyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.
  • alkynyl denotes in each case a singly unsaturated hydrocarbon rad- ical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. ethynyl, pro- pargyl (2-propyn-1 -yl), 1-propyn-1-yl, 1-methylprop-2-yn-1 -yl), 2-butyn-1 -yl, 3-butyn-1-yl, 1-pen- tyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-methylbut-2-yn-1 -yl, 1-ethylprop-2-yn-1-yl and the like.
  • haloalkynyl refers to an alkynyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.
  • cycloalkyl as used herein and in the cycloalkyl moieties of cycloalkoxy and cycloal- kylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • halocycloalkyl as used herein and in the halocycloalkyl moieties of halocycloalkoxy and halocycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 C atoms or 3 to 6 C atoms, wherein at least one, e.g. 1 , 2, 3, 4, or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine.
  • Examples are 1 - and 2- fluorocyclopropyl, 1 ,2-, 2,2- and 2,3-difluorocyclopropyl, 1 ,2,2-trifluorocyclopropyl, 2,2,3,3-tetra- fluorocyclpropyl, 1 - and 2-chlorocyclopropyl, 1 ,2-, 2,2- and 2,3-dichlorocyclopropyl, 1 ,2,2-trichlo- rocyclopropyl, 2,2,3,3-tetrachlorocyclpropyl, 1-,2- and 3-fluorocyclopentyl, 1 ,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1 -,2- and 3-chlorocyclopentyl, 1 ,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-dichlo- rocyclopentyl and the like.
  • cycloalkoxy refers to
  • halocycloalkoxy refers to a halocycloalkyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • cycloalkylthio refers to a cycloalkyl group as defined above, which is bonded via a sulfur atom to the remainder of the molecule.
  • halocycloalkylthio refers to a halocycloalkyl group as defined above, which is bonded via a sulfur atom to the remainder of the molecule.
  • cycloalkenyl as used herein and in the cycloalkenyl moieties of cycloalkenyloxy and cycloalkenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical having usually from 3 to 10, e.g. 3, or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms.
  • exemplary cycloalkenyl groups include cyclopropenyl, cycloheptenyl or cyclo- octenyl.
  • halocycloalkenyl as used herein and in the halocycloalkenyl moieties of halocyclo- alkenyloxy and halocycloalkenylthio denotes in each case a monocyclic singly unsaturated non- aromatic radical having usually from 3 to 10, e.g. 3, or 4 or from 5 to 10 carbon atoms, prefera- bly from 3- to 8 carbon atoms, wherein at least one, e.g. 1 , 2, 3, 4, or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine. Examples are 3,3-difluorocyclopro- pen-1 -yl and 3,3-dichlorocyclopropen-1-yl.
  • cycloalkenyloxy refers to a cycloalkenyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • halocycloalkenyloxy refers to a halocycloalkenyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.
  • cycloalkenylthio refers to a cycloalkenyl group as defined above, which is bonded via a sulfur atom to the remainder of the molecule.
  • halocycloalkenylthio refers to a halocycloalkenyl group as defined above, which is bonded via a sulfur atom to the remainder of the molecule.
  • carrier or “carbocyclyl” includes in general a 3- to 12-membered, preferably a 3- to 8-membered or a 5- to 8-membered, more preferably a 5- or 6-membered mono-cyclic, non-aromatic ring comprising 3 to 12, preferably 3 to 8 or 5 to 8, more preferably 5 or 6 carbon atoms.
  • the term “carbocycle” covers cycloalkyl and cycloalkenyl groups as defined above.
  • heterocycloalkyl includes in general 3- to 8-membered, in particular 6-membered monocyclic saturated heterocyclic non-aromatic radicals.
  • the heterocyclic non-aromatic radicals usually comprise 1 , 2, or 3 heteroatoms selected from N, O and S as ring members, where S- atoms as ring members may be present as S, SO or SO2.
  • heterocycloalkenyl includes in general 3- to 8-membered, in particular 6-membered monocyclic singly unsaturated heterocyclic non-aromatic radicals.
  • the heterocyclic non-aromatic radicals usually comprise 1 , 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2.
  • heterocycle or “heterocyclyl” includes in general 3- to 12-membered, preferably 3- to 8-membered or 5- to 8-membered, more preferably 5- or 6-membered, in particular 6-membered monocyclic heterocyclic non-aromatic radicals.
  • the heterocyclic non-aromatic radicals usually comprise 1 , 2, 3, 4, or 5, preferably 1 , 2 or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2.
  • Examples of 5- or 6-membered heterocyclic radicals comprise saturated or unsaturated, non-aromatic heter- ocyclic rings, such as oxiranyl, oxetanyl, thietanyl, thietanyl-S-oxid (S-oxothietanyl), thietanyl-S- dioxid (S-dioxothiethanyl), pyrrolidinyl, pyrrolinyl, pyrazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1 ,3-dioxolanyl, thiolanyl, S-oxothiolanyl, S-dioxothiolanyl, dihydrothienyl, S-oxodihydrothienyl, S- dioxodihydrothienyl, oxazolidinyl, oxazolinyl, thiazolinyl,
  • aryl includes mono-, bi- or tricyclic aromatic radicals having usually from 6 to 14, preferably 6, 10, or 14 carbon atoms.
  • Exemplary aryl groups include phenyl, naphthyl and an- thracenyl. Phenyl is preferred as aryl group.
  • heteroaromatic radicals include monocyclic 5- or 6-membered heteroaromatic radicals comprising as ring members 1 , 2, 3, or 4 heteroatoms selected from N, O and S.
  • 5- or 6-mem- bered heteroaromatic radicals include pyridyl, i.e. 2-, 3-, or 4-pyridyl, pyrimidinyl, i.e. 2-, 4-, or 5- pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- or 4-pyridazinyl, thienyl, i.e. 2- or 3-thienyl, furyl, i.e. 2- or 3-furyl, pyrrolyl, i.e.
  • 2- or 3-pyrrolyl oxazolyl, i.e. 2-, 3-, or 5-oxazolyl, isoxazolyl, i.e. 3-, 4-, or 5-isoxazolyl, thiazolyl, i.e. 2-, 3- or 5-thiazolyl, isothiazolyl, i.e. 3-, 4-, or 5-isothiazolyl, pyrazolyl, i.e. 1 -, 3-, 4-, or 5-pyrazolyl, i.e. 1 -, 2-, 4-, or 5-imidazolyl, oxadiazolyl, e.g.
  • heteroaryl also includes bicyclic 8 to 10-membered heteroaromatic radicals comprising as ring members 1 , 2 or 3 heteroatoms selected from N, O and S, wherein a 5- or 6-membered heteroaromatic ring is fused to a phenyl ring or to a 5- or 6- membered heteroaromatic radical.
  • Examples of a 5- or 6-membered heteroaromatic ring fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical include benzofuranyl, benzo- thienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, chinolinyl, isochinolinyl, purinyl, 1 ,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl or pyridoimidazolyl and the like.
  • fused hetaryl radicals may be bonded to the remainder of the molecule via any ring atom of 5- or 6-membered heteroaromatic ring or via a carbon atom of the fused phenyl moiety.
  • heterocyclyloxy refers to heterocyclyl, hetaryl and aryl as defined above and phenyl, which are bonded via an oxygen atom to the remainder of the molecule.
  • heterocyclylsulfonyl refers to heterocyclyl, hetaryl and aryl as defined above, and phenyl, respectively, which are bonded via the sulfur atom of a sulfonyl group to the remainder of the molecule.
  • arylalkyl and phenylalkyl refer to aryl as defined above and phenyl, respectively, which are bonded via d-Cs-alkyl group or a Ci-C4-alkyl group, in particular a methyl group
  • arylalkoxy and benzyloxy refer to arylalkyl as defined above and phenyl-Ci-alkyl, respectively, which are bonded via an oxygen atom, to the remainder of the molecule.
  • alkylene refers to alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cy- cloalkenyl, heterocycloalkenyl and alkynyl as defined above, respectively, which are bonded to the remainder of the molecule, via two atoms, preferably via two carbon atoms, of the respective group, so that they represent a linker between two moieties of the molecule.
  • cyclic moiety can refer to any cyclic groups, which are present in the compounds of the present invention, and which are defined above, e.g. cycloalkyl, cycloalkenyl, carbocycle, heterocycloalkyl, heterocycloalkenyl, heterocycle, aryl, hetaryl and the like.
  • the compounds of formula V of the present invention can be obtained according to the sequence comprising the steps (a) I -> II, (b) II + III -> IV, and (c) IV -> V as described above and herein after, and in view of the fact that the compounds of formula V, if provided e.g.
  • the substituent R 1 is present in the 4-position of the pyrazole ring of the compounds of formula V.
  • the substituent R 1 is also present in the precursors III and IV of the compounds of formula V.
  • R 1 is
  • Ci-Cio-alkyl which is unsubstituted, partially or fully halogenated, or substituted by 1 , 2 or 3 identical or different substituents R x , or
  • R c is H, Ci-C4-alkyl or aryl-Ci-C4-alkyl, or wherein R c together with the C(Y)0 group forms a salt [C(Y)0]-NH 4 + , [C(Y)0]-M a + or [C(Y)0]-1 ⁇ 2M ea 2+ , wherein M a is an alkali metal and M ea is an alkaline earth metal;
  • R d is Ci-C 4 -alkyl, C3-C6-cycloalkyl, aryl or hetaryl;
  • Y 1 is O or NR 1a , wherein R 1a is Ci-C 4 -alkyl, C3-C6-cycloalkyl, aryl or hetaryl.
  • R 1 is CN or C(Y)OR c , wherein Y is O and R c is Ci-C 4 -alkyl or benzyl.
  • R c is preferably ethyl, tert-butyl, or benzyl, and more preferably ethyl or tert-butyl.
  • R 1 is C(0)OCH 2 CH 3 .
  • the substituent R 2 is present in the 5-position of the pyrazole ring of the compounds of formulae V, Va, Vb, Vc, VI and VIII. Furthermore, the substituent R 2 is present in the precursors III and IV of the compounds of formula V.
  • R 2 is
  • Ci-Cio-alkyl which is unsubstituted, partially or fully halogenated, or substituted by 1 , 2 or 3 identical or different substituents R x ,
  • R 2 is Ci-C 4 -alkyl, which is unsubstituted, or partially or fully halogenated.
  • R 2 is CH3, CH2CH3 or fluoromethyl, and particularly preferred that R 2 is CH 3 , CF 2 H or CF 3 .
  • R 2 is CH 3 .
  • the substituent R 3 is present in the 3-position of the pyrazole ring of the compounds of formulae V, Va, Vb, Vc, VI and VIII. Furthermore, the substituent R 3 is present in the precursors III and IV of the compounds of formula V. In a preferred embodiment of the invention R 3 is
  • Ci-Cio-alkyl which is unsubstituted, partially or fully halogenated, or substituted by 1 , 2 or 3 identical or different substituents R x ,
  • R 3 is H.
  • the process according to the present invention is particularly advantageous for regioselectively preparing N-substituted pyrazole compounds, which are 3- or 5- subsituted or substituted with different substituents in the 3- and 5-position.
  • compounds of formula V, wherein R 3 and R 2 are different from each other are particularly preferred. It is particularly preferred that one of R 3 and R 2 is H and the other one is different from H. Alternatively, it can be preferred that R 3 and R 2 are both different from H , and different from each other.
  • R 2 is CH3 and R 3 is H.
  • the substituents R 4 and R 5 are present in the compounds of formulae I, II, IV, V, Va, Vb, Vc, VI and VIII.
  • R 4 is selected from Ci-Cio-alkyl, which is unsubstituted, partially or fully halogenated, or substi- tuted by 1 , 2 or 3 identical or different substituents R x , and
  • R 5 is selected from Ci-Cio-alkyl, which is unsubstituted, partially or fully halogenated, or substituted by 1 , 2 or 3 identical or different substituents R x , and
  • R 4 is selected from Ci-C4-alkyl, which is unsubstituted, partially or fully halogenated, or substituted by 1 or 2 identical or different substituents R x , wherein R x is selected from CN and
  • R 5 is selected from Ci-C4-alkyl, which is unsubstituted, partially or fully halogenated, or substituted by 1 or 2 identical or different substituents R x , wherein R x is selected from CN and
  • R 4 is selected from Ci-C4-alkyl, which is unsubstituted, partially or fully halogenated, or substi- tuted by 1 or 2 identical or different substituents R x , wherein R x is selected from CN and
  • C3-C6-cycloalkyl which is unsubstituted or substituted by 1 , 2 or 3 identical or different substituents Ry, wherein Ry is selected from halogen, CN and C(0)NH2; and R 5 is selected from Ci-C2-alkyl, which is unsubstituted, partially or fully halogenated, or substituted by 1 or 2 identical or different substituents R x , wherein R x is selected from CN and
  • C3-C4-cycloalkyl which is unsubstituted or substituted by 1 , 2 or 3 identical or different substit- uents R y , wherein R y is selected from halogen, CN and C(0)NH2.
  • R 4 and R 5 are different from each other.
  • R 5 may be Ci-C2-alkyl, which is unsubstituted, or C3-C4-cycloalkyl, which is unsubstituted
  • R 4 may be Ci-C4-alkyl, which is unsubstituted, or partially or fully halogenated, or substituted with 1 or 2 identical or different substituents R x selected from CN and C(0)NH2, or may be C3-C6-cycloalkyl, which is preferably substituted with 1 , 2 or 3 identical or different substituents R y selected from halogen, CN and C(0)NH 2 .
  • R 5 is CH3, while R 4 is Ci-C4-alkyl, Ci-C2-haloalkyl, or C3-cycloalkyl, wherein the cycloalkyl group is preferably substituted with one substituent selected from CN and
  • R 5 and R 4 may thus e.g. be CH 3 /i-Pr or CH3/I -CN-CC3H4.
  • R 5 and R 4 may thus e.g. be CH 3 /i-Pr or CH3/I -CN-CC3H4.
  • R 4 and R 5 together with the carbon atom to which they are attached form a 3- to 12-membered non-aromatic carbocycle, which is unsubstituted or partially or fully substituted by Ri.
  • R 4 and R 5 together with the carbon atom to which they are attached form a 3- to 12-membered non-aromatic, saturated carbocycle, which is unsubstituted or partially or fully substituted by Ri, wherein Ri is selected from halogen, CN and C(0)NH2.
  • R 4 and R 5 together with the carbon atom to which they are attached form a 3- to 6-membered non-aromatic, saturated carbocycle, which is unsubstituted or partially or fully substituted by Ri, wherein Ri is selected from halogen, CN and C(0)NH2.
  • R 4 and R 5 together with the carbon atom to which they are attached form a 6-membered carbocycle, which is partially or fully halogenated, preferably fluorinated.
  • R 4 and R 5 may together represent e.g. -CH2CH2CF2CH2CH2-.
  • R 1 is CN or C(Y)OR c ,
  • Y is O, and R c is Ci-C4-alkyl or benzyl;
  • R 2 is Ci-C4-alkyl, which group is unsubstituted, or partially or fully halogenated, preferably CH3, or halomethyl; CH3 is particularly preferred;
  • R 3 is H
  • R 4 is selected from Ci-C4-alkyl, which group is unsubstituted, partially or fully halogenated, and
  • R 5 is selected from Ci-C4-alkyl, which group is unsubstituted, partially or fully halogenated, and C3-C6-cycloalkyl, which group is unsubstituted or substituted by one or more identical or different substituents R y , wherein R y is selected from halogen and CN.
  • R 1 is C(0)OR c , wherein R c is Ci-C 4 -alkyl or benzyl;
  • R 2 is CH 3 or fluoromethyl; CH 3 is particularly preferred;
  • R 3 is H
  • R 4 is selected from Ci-C 4 -alkyl, which group is unsubstituted or partially halogenated, and R 5 is selected from Ci-C 4 -alkyl, preferably CH3.
  • R 1 is C(0)OCH 2 CH 3 ;
  • R 2 is CH 3 ;
  • R 3 is H;
  • R 4 is CH(CH 3 ) 2 ; and
  • R 5 is CH 3 .
  • Table 14 Combination, in which R 1 is C(0)OCH 3 , R 2 is CFH 2 , R 3 is H and the combination of R 4 and R 5 corresponds in each case to one row of Table A
  • Table 15 Combination, in which R 1 is C(0)OCH 2 CH 3 , R 2 is CFH 2 , R 3 is H and the combination of R 4 and R 5 corresponds in each case to one row of Table A
  • Table 35 Combination, in which R 1 is C(0)OCH 2 C 6 H 5 , R 2 is CF 3 , R 3 is H and the combination of R 4 and R 5 corresponds in each case to one row of Table A
  • Table 36 Combination, in which R 1 is CN, R 2 is CF3, R 3 is H and the combination of R 4 and R 5 corresponds in each case to one row of Table A
  • R 1 is CF 3
  • R 2 is C(0)NH-(3-C(0)NHCH 2 C6H5,4-CI-C 6 H3)
  • R 3 is C2F5 and the combination of R 4 and R 5 corresponds in each case to one row of Table A
  • the present invention relates to a catalytic process for preparing pyrazole compounds V comprising the step of cyclizing hydrazone substituted ⁇ , ⁇ -unsaturated carbonyl compounds IV, i.e.
  • pyrazole precursors IV by reacting them with hydrogen in a reaction mixture comprising as components (a) a hydrogenation catalyst, (b) an acid selected from Bransted acids, ammonium salts of Br0nsted acids, and Lewis acids, (c) a protic solvent; and optionally (d) an aprotic solvent.
  • step (c) said reaction step is referred to as step (c).
  • the process may further comprise reaction steps (a) and (b) as defined above for the preparation of the pyrazole precursors IV, and reaction steps (d), (e) and (f) for further transformations of the pyrazole compounds V.
  • the present invention partic- ularly focuses on the cyclization of the pyrazole precursors IV according to step (c) as defined above to obtain the pyrazole compounds V.
  • reaction steps (a) to (f), in particular regarding reaction step (c) of the invention are defined in further detail hereinafter.
  • reaction steps are performed in reaction vessels customary for such reactions, the reactions being carried out in a continuous, semi-continuous or batchwise manner.
  • reaction steps are preferably carried out under atmospheric pressure.
  • reaction step (c) may also be carried out under a hydrogen pressure of more than 1 bar (more than 100 kPa), preferably of at least 5 bar, more preferably from 1 to 50 bar, for technical rea- sons a pressure of from 5 to 20 bar is usually applied.
  • the temperatures and the duration times of the reactions may be varied in broad ranges, which the person skilled in the art knows from analogous reactions.
  • the temperatures often depend on the reflux temperature of the solvents.
  • Other reactions are preferably performed at room temperature, i.e. at 25°C, or at 0°C.
  • the end of the reaction can be monitored by methods known to a person skilled in the art, e.g. thin layer chromatography or HPLC.
  • the molar ratios of the reactants, which are used in the reactions are in the range of from 0.2:1 to 1 :0.2, preferably from 0.5:1 to 1 :0.5, more preferably from 0.8:1 to 1 :0.8.
  • equimolar amounts are used.
  • reactants can in principle be contacted with one another in any desired sequence.
  • reaction step (c) of the process of the present invention is described hereinafter.
  • the preferred embodiments mentioned above and those still to be illustrated below of reaction step (c) of the process of the invention are to be understood as preferred alone or in combination with each other.
  • the pyrazole precursor IV is provided in a reaction mixture comprising as components
  • reaction mixture comprising as components
  • reaction mixture is pressurized with hydrogen
  • the dosing rate of the compound IV solution to the reaction mixture depends on the amount of reactants. A slower dosing usually increases the yield and selectivity of the pyrazole V. Dosing time depends on the volume of the solution to be dosed and of the reaction vessel. For practical reasons the dosing is completed in up to 12 hours, preferably up to four hours. After completion of dosing the reaction is completed after another one to two hours stirring.
  • hydrogenation catalyst covers heterogeneous and homogeneous hydrogenation catalysts, but preferably refers to heterogeneous catalysts. It is known in the art that platinum, palladium, rhodium, and ruthenium form highly active catalysts. Non-precious metal catalysts, such as catalysts based on nickel (such as Raney nickel and Urushibara nickel) are economical alternatives. Preferred hydrogenation catalysts according to the invention are provided further below.
  • the hydrogenation catalyst comprises platinum or palladium.
  • the platinum or palladium may be provided on a carrier, for example on carbon, calcium carbonate, strontium carbonate, barium carbonate, alumina, barium sulphate, kieselguhr, or magnesium silicate.
  • the platinum or palladium is provided on carbon.
  • the hydrogenation catalyst is selected from Pd/C, Pt/C, and Pt0 2 .
  • platinum catalysts are particularly advantageous in terms of increasing the yields of the desired pyrazoles V and in terms of the prevention of the formation of the unde- sired NH-pyrazoles V H .
  • the hydrogenation catalyst is therefore selected from Pt/C and PtC>2. It is most preferred in the context of the present invention that the hydrogenation catalyst is Pt/C.
  • the hydrogenation catalyst is present in the reaction mixture in an amount of at least 0.05 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst is present in an amount of at least 0.1 mol%, more preferably at least 0.3 mol%. It can also be preferred to use at least 0.5 mol%.
  • Suitable amounts may thus be in the range of from 0.05 to 5.0 mol%, preferably from 0.1 to 1 .0 mol% or from 0.5 to 1 .0 mol% based on the molar amount of the pyrazole precursor IV. However, in a fixed bed case, also amounts of more than 5.0 mol% may be used.
  • the hydrogenation catalyst comprises Pt or Pd, and is present in an amount of at least 0.05 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst comprises Pt or Pd, and is present in an amount of at least 0.1 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst comprises Pt or Pd, and is present in an amount of at least 0.5 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst is PtC>2, and is present in an amount of at least 0.05 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst is PtC>2, and is present in an amount of at least 0.1 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst is PtC>2, and is present in an amount of at least 0.5 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst is Pt/C, and is present in an amount of at least 0.05 mol% based on the molar amount of the pyrazole precursor IV.
  • the hydrogenation catalyst is Pt/C, and is present in an amount of at least 0.1 mol% based on the molar amount of the pyrazole precursor IV. In another preferred embodiment, the hydrogenation catalyst is Pt/C, and is present in an amount of at least 0.5 mol% based on the molar amount of the pyrazole precursor IV.
  • the acid in the reaction mixture is selected from Br0nsted acids, ammonium salts of Bransted acids, and Lewis acids.
  • the term "Bransted acid” refers to an acid, which donates a proton in an acid- base reaction.
  • a Bransted acid HA may be considered as dissociating into A- and H + .
  • the pK a value defines the strength of the Bransted acid. The larger the value of pK a , the smaller the extent of dissociation at any given pH (Henderson-Hasselbalch equation) that is, the weaker the acid.
  • the pK a values are measured in dilute aqueous solutions at room temperature (i.e. 25 °C).
  • the pK a values for many acids in water are well known and may be found in available references, such as D. H. Rippin, D. A. Evans, Chem 206 (1 1/4/05).
  • pK a values are acceptable for the Bransted acid acids as used ac- cording to the present invention.
  • a Bransted acid with a pK a of less than 6, preferably lass than 5 or less than 4.5 Preferably, the pK a may be in the range of from -3 to 6, preferably from -3 to 5 or from -3 to 4.5. Rather strong Br0nsted acids with a pK a of from -3 to 3 may advantageously be used. In case of rather strong Bransted acids with a pK a of from -3 to 3, it can be preferred to use rather low amounts of the acid as defined further below.
  • a weaker Bransted acid with a pK a in the range of from -0.5 to 6, preferably from -0.5 to 5 or even from more than 3 to 5.
  • a weaker Br0nsted acids it can be preferred to use higher amounts of the acid as defined further below.
  • the Bransted acid is selected from Ci-C4-alkanoic acids, Ci-C4-haloalka- noic acids, aryl carboxylic acids, Ci-C4-alkyl sulfonic acids, aryl sulfonic acids, cycloaliphatic sulfonic acids, sulfuric acid, oxyacids of phosphor, and hydrogen halides.
  • Ci-C4-Alkanoic acids in particular acetic acid and formic acid may at the same time be used as protic solvents in the reaction mixture.
  • the Bransted acid is therefore selected from Ci-C4-alkanoic acids.
  • the Br0nsted acid is selected from Ci-C4-haloalkanoic acids, aryl carboxylic acids, Ci-C4-alkyl sulfonic acids, aryl sulfonic acids, cycloaliphatic sulfonic acids, sulfuric acid, oxyacids of phosphor, and hydrogen halides.
  • Ci-C4-alkanoic acids refers to carboxylic acids R A -C02H, wherein the group R A is selected from Ci-C4-alkyl.
  • Examples of Ci-C4-alkanoic acids are formic acid, acetic acid, propionic acid, and butyric acid.
  • Preferred Ci-C4-alkanoic acids, which may also be used as protic solvents, are formic acid and acetic acid, in particular acetic acid (AcOH).
  • Ci-C4-haloalkanoic acids refers to carboxylic acids R B -C02H, wherein the group R B is selected from Ci-C4-haloalkyl.
  • Preferred halogenated acetic acids include trifluoroacetic acid (TFA), trichloroacetic acid (TCAA), and chloroacetic acid (CI-AcOH).
  • a preferred halogenated acetic acid is trifluoroacetic acid (TFA).
  • the aryl group itself may be phenyl or naphthyl.
  • aryl carboxylic acids are benzoic acid, 4-methylbenzoic acid, 2-methylbenzoic acid, 2,4-dimethylbenzoic acid, 4-chlorobenzoic acid, 1 -naphthalenecarboxylic acid, 2-naphtha- lenecarboxylic acid, 2-methyl-1 -naphthalenecarboxylic acid, 4-methyl-2-naphthalenecarboxylic acid, 6-methyl-2-naphthalenecarboxylic acid, 1 ,4-dimethyl-2-naphthalenecarboxylic acid, 1 ,5- dimethyl-2-naphthalenecarboxylic acid, and 5,6-dimethyl-2-naphthalenecarboxylic acid.
  • a pre- ferred aryl carboxylic acid is benzoic acid (C6H5-COOH).
  • Ci-C4-alkyl sulfonic acids refers to sulfonic acids R D -S03H, wherein R D is Ci-C4-alkyl.
  • a preferred Ci-C4-alkyl sulfonic acid is methylsulfonic acid (MSA).
  • aryl sulfonic acids refers to sulfonic acids R E -SOsH, wherein R E is aryl, wherein the aryl group is unsubstituted or partly or fully substituted by identical or different substituents selected from halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, and Ci-C4-alkoxy.
  • the aryl group itself may be phenyl or naphthyl.
  • aryl sulfonic acids are benzenesulfonic acid, 4-toluenesulfonic acid, 2-toluenesulfonic acid, 2,4-xylenesulfonic acid, 1 -naphthalenesul- fonic acid, 2-naphthalenesulfonic acid, 2-methyl-1-naphthalenesulfonic acid, 4-methyl-2-naph- thalenesulfonic acid, 6-methyl-2-naphthalenesulfonic acid, 1 ,4-dimethyl-2-naphthalenesulfonic acid, 1 ,5-dimethyl-2-naphthalenesulfonic acid, and 5,6-dimethyl-2-naphthalenesulfonic acid.
  • a preferred aryl sulfonic acid is 4-toluenesulfonic acid, i.e. p-toluenesulfonic acid (PTSA).
  • cycloaliphatic sulfonic acids describes sulfonic acids R F -S03H, wherein the R F is selected from C3-Cio-cycloalkyl and C3-Cio-cycloalkyl-Ci-C4-al- kyl, wherein C3-Cio-cycloalkyl in each case is a mono- or bicyclic moiety, which is unsubstituted or substituted by one or more identical or different substituents selected from bromine, chlorine, Ci-C4-alkyl, or two of said substituents positioned at the same carbon atom represent the oxy- gen atom of a carbonyl group.
  • Examples of cycloaliphatic sulfonic acids are cyclohexane sulfonic acid and camphorsulfonic acid.
  • sulfuric acid refers to H2SO4.
  • oxyacids of phosphor encompasses any acid, which has a OH- group or NH2 group bound to phosphor, especially an acid having 1 , 2 or 3 OH groups or 1 NH2 group, which are bound to a phosphor atom in the oxidation state III or V.
  • Phosphoric acid its oligomers and its mono- or di-estersorthophosphoric acid (H3PO4), pyrophosphoric acid, polyphosphoric acids, aryl dihydrogen phosphates, such as phenyl dihy- drogen phosphate or 1 -naphthyl dihydrogen phosphate, alkyl dihydrogen phosphate, such as butyl dihydrogen phosphate or 2-ethylhexyl dihydrogen phosphate, benzyl dihydrogen phosphate and substituted derivatives thereof,
  • Phosphinic acids e.g. Aryl phosphinic acids, such as phenyl phosphinic acid, Phosphoric amidates, such as diethyl phosphoramidate, dibenzylphospho-ramidate or dibenzyl phosphoramidate.
  • a preferred oxyacid of phosphor is phosphoric acid (H3PO4).
  • hydrogen halide preferably includes HF, HCI, HBr, and HI, and is preferably HCI.
  • ammonium salts of Bransted acids denotes salts obtained by neutralizing Br0nsted acids, in particular those mentioned before as preferred, with ammonia or organic amines.
  • organic amines are preferably selected from aromatic amines, such as pyridine or collidine, heterocyclic amines, such as piperidine, 2,2,6,6-tetramethylpiperi- dine, 2,2,6,6-tetramethylpiperidone or morpholine, aryl amines, such as aniline or 4-methylani- line, secondary and tertiary mixed alkyl-aryl amines, such as N-methyl aniline or N,N-dimethyl aniline, and primary, secondary and tertiary aliphatic amines, such as triethylamine, diethyla- mine, 1 -propylamine or 2-cyclopropyl-2-propylamine, particularly selected from pyridine, collidine, morpholine and trimethylamine, and specifically selected
  • Preferred Lewis acids for the process according to the invention are selected from halides of metals and metalloids and derivatives thereof. It is to be understood that the term “halides of metals and metalloids” also covers their complexes with Lewis bases, such as Et.20. These complexes (e.g. BF3*OEt2, wherein BF3 is the "halide of a metal or metalloid" and Et ⁇ O is the Lewis base) typically dissociate under the reaction conditions to provide the Lewis acid.
  • Lewis bases such as Et.20.
  • Lewis acids examples include MgF 2 , BF 3 *OEt 2 , BCI 3 , AICI 3 , AIF 3 , ZnC , FeCI 3 , PF 5 , SbF 5 , TiCU, B1CI3, GaCb, SnCU and SiCI 4 .
  • the Lewis acid used in the process of the invention is selected from BF 3 *OEt 2 , FeC , TiCU and AICI3 with AICI3 being particu- larly preferred.
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • a Bransted acid selected from Ci-C4-alkanoic acids, Ci-C4-haloalkanoic acids, aryl car- boxylic acids, Ci-C4-alkyl sulfonic acids, aryl sulfonic acids, cycloaliphatic sulfonic acids, sulfuric acid, oxyacids of phosphor, and hydrogen halides,
  • (b3) a Lewis acid selected from halides of metals and metalloids.
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • a Bransted acid selected from Ci-C4-haloalkanoic acids, Ci-C4-alkyl sulfonic acids, aryl sulfonic acids, sulfuric acid, oxyacids of phosphor, and hydrogen halides,
  • a Bransted acid selected from Ci-C4-haloalkanoic acids, Ci-C4-alkyl sulfonic acids, aryl sulfonic acids, sulfuric acid, oxyacids of phosphor, and hydrogen halides
  • a Lewis acid selected from halides of metals and metalloids.
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • (b2) an ammonium salt of a Bransted acid with a pK a of -3 to 3, or (b3) a Lewis acid selected from halides of metals and metalloids.
  • the acid is
  • a Bransted acid selected from acetic acid (AcOH), trifluoroacetic acid (TFA), trichloroace- tic acid (TCAA), chloroacetic acid (CI-AcOH), methylsulfonic acid (MSA), p-toluenesulfonic acid (PTSA), sulfuric acid (H2SO4), and phosphoric acid (H3PO4),
  • a pyridinium or trimethylammonium salt of a Bransted acid selected from acetic acid (AcOH), trifluoroacetic acid (TFA), trichloroacetic acid (TCAA), chloroacetic acid (CI-AcOH), methylsulfonic acid (MSA), p-toluenesulfonic acid (PTSA), sulfuric acid (H2SO4), and phosphoric
  • (b3) a Lewis acid selected from BF 3 * OEt 2 , FeCI 3 , TiCU, and AICI3.
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • a Bransted acid selected from acetic acid (AcOH), trifluoroacetic acid (TFA), trichloroacetic acid (TCAA), sulfuric acid (H2SO4), and phosphoric acid (H3PO4),
  • (b3) a Lewis acid selected from BF 3 * OEt 2 , FeCI 3 , TiCU, and AICI 3 .
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • a Bransted acid selected from trifluoroacetic acid (TFA), and sulfuric acid (H2SO4), (b2) pyridinium methylsulfonate (MSA * pyr), or
  • (b3) a Lewis acid selected from BF 3 * OEt 2 , FeCI 3 , TiCU, and AICI3.
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • (b3) a Lewis acid selected from BF 3 * OEt 2 , and AICI3-
  • the acid is AcOH, TFA, TCAA, CI-AcOH, C 6 H 5 -COOH,
  • MSA, PTSA, H2SO4, or H 3 P0 4 more preferably AcOH, TFA, TCAA, H 2 S0 4 , or H 3 P0 4 .
  • the acid is TFA, TCAA, or H2SO4.
  • the acid is H 3 P0 4 , TFA, or H 2 S0 4 , particularly H 2 S0 4 .
  • the acid is H 3 P04.
  • the acid is TFA.
  • the acid is H2SO4.
  • the acid is a pyridinium or trimethylammonium salt of AcOH, TFA, TCAA, CI-AcOH, MSA, PTSA, H 2 S0 4 , or H 3 P0 4 .
  • the acid is MSA * pyr.
  • the acid is BF 3 * OEt2, FeCI 3 , TiCU, or AICI3.
  • the acid is BF 3 * OEt2.
  • the acid is FeCI 3 .
  • the acid is TiCU.
  • the acid is AICI3- It is to be understood that also combinations of the above defined acids can be used. For example, a combination of a (b1 ) a Bransted acid and (b3) a Lewis acid may preferably be used.
  • the amounts of the acid may be varied depending on the costs and the acidity. As outlined above, acetic acid, which is rather cheap, may advantageously be used in amounts, so that it can also serve as protic solvent. For example, 10 equivalents or more of acetic acid may then be used in comparison to the pyrazole precursor IV (wherein the equivalents refer to the molar amounts). Other acids may be added to the reaction mixture in stoichio- metric amounts or in substochiometric amounts.
  • the acid is present in the reaction mixture in an amount of at least 0.05 mol% based on the molar amount of the pyrazole precursor IV, preferably, the acid is present in the reaction mixture in an amount of at least 0.1 mol%. More preferably, the acid is present in the reaction mixture in an amount of at least 1 mol% based on the mo- lar amount of the pyrazole precursor IV. It is particularly preferred that the acid is present in an amount of at least 5 mol% based on the molar amount of the pyrazole precursor IV. In certain cases, it can also be preferred to use at least 40 mol % of the acid or at least 80 mol% of the acid based on the molar amount of the pyrazole precursor IV.
  • the preferred amount of the acid depends on the nature of the acid.
  • the acid which is preferably a Br0nsted acid, is used in an amount of about one equivalent, i.e. 0.9 to 1 .2 mol equivalents to compound of formula IV.
  • the acid which is preferably a Br0nsted acid
  • the acid may also be used in rather high amounts. If the acid also serves as protic solvent, a large excess of the acid will in any case be present. In other cases, amounts up to 200 mol% (i.e. 2 equiv.) can be suitable.
  • preferred amounts of the acid may be in the range of from 0.05 to 200 mol%, preferably from 0.1 to 200 mol %, more preferably from 1 to 200 mol% based on the molar amount of the pyrazole precursor IV.
  • a preferred range is from 5 to 200 mol%.
  • 5 to 15 mol%, 15 to 25 mol %, 25 to 35 mol%, 35 to 45 mol%, 45 to 55 mol%, 55 to 65 mol%, 65 to 75 mol%, 75 to 85 mol%, 85 to 95 mol%, or 95 to 105 mol% may be used.
  • Bransted acids are typically used in higher amounts than Lewis acids.
  • Bransted acids are used in an amount of at least 1 mol%, preferably at least 5 mol%, more preferably at least 40 mol%, based on the molar amount of the pyrazole precursor IV. Suitable amounts may vary depending on the strength of the acid.
  • Bransted acids with a pK a of from more than 3 to 5 it is preferred to use amounts of at least 5 mol%, preferably at least 40 mol%. It can be suitable to use amounts of from 40 mol% to 200 mol%, or the acid may be used as protic solvent, e.g. in amounts of 10 equivalents or more.
  • ammonium salts of Bransted acids are used in an amount of at least 5 mol%, preferably at least 40 mol% based on the molar amount of the pyrazole precursor IV.
  • a preferred range is from 40 mol% to 200 mol%.
  • Lewis acids are used in an amount of at least 1 mol%, preferably at least 5 mol% based on the molar amount of the pyrazole precursor IV.
  • a preferred range is from 1 mol% to 200 mol%, preferably from 5 mol% to 100 mol%.
  • the following combinations B-1 to B-14 of the hydrogenation catalyst (component (a)) and the acid (component (b)) as defined in Table B are preferred according to the present invention.
  • combinations B-1 to B-7 are combinations B-1 to B-7, with combination B-1 , B-2, and B-7 being particularly preferred in terms of the yields and B-1 , B-4, and B-7 being particularly preferred in terms of the selectivity of the cyclization reaction.
  • protic solvent generally includes solvents that have a hydrogen atom bound to an oxygen atom (as in a hydroxyl group) or a nitrogen atom (as in an amine group), so that they can principally donate protons (H + ) to reagents.
  • Preferred protic solvents include Ci-C4-alkanols, C 2 -C4-alkandiols, ether alkanols, water, acetic acid, formic acid, and mixtures thereof.
  • Ci-C4-alkanols generally include methanol, ethanol, propanol, isopropanol, n-butanol, sec-bu- tanol, and tert-butanol.
  • Preferred Ci-C4-alkanols include methanol (MeOH), ethanol (EtOH), n- propanol and isopropanol.
  • Preferred are methanol and ethanol.
  • Particularly preferred is ethanol.
  • Another particularly preferred solvent is methanol.
  • Preferred C 2 -C4-alkandiols include ethylene glycol or propylene glycol.
  • Preferred ether alkanols include as diethylene glycol.
  • the protic solvent is selected from Ci-C4-alkanols, water, acetic acid, formic acid, and mixtures thereof.
  • An exemplary mixture is ethanol/acetic acid.
  • the protic solvent is acetic acid.
  • the protic solvent is selected from Ci-C4-alkanols and mixtures thereof.
  • the protic solvent is methanol or ethanol or isopropanol. In a particularly preferred embodiment, the protic solvent is ethanol.
  • combinations C-1 to C-3 are particularly preferred.
  • aprotic solvent refers to solvents that cannot donate protons.
  • the aprotic solvent is only an optional component of the reaction mixture of the invention, and may for example be present as a co-solvent.
  • the aprotic solvent is selected from aromatic solvents, alkane solvents, ether solvents, ester solvents, and mixtures thereof.
  • Preferred aromatic solvents are e.g. benzene, toluene, xylene (ortho-xylene, meta-xylene or para-xylene), mesitylene, chlorobenzene (MCB), 1 ,2-dichlorobenzene, 1 ,3-dichlorobenzene, 1 ,4-dichlorobenzene, or mixtures thereof. More preferred aromatic solvents are selected from toluene, xylene (ortho-xylene, meta-xylene or para-xylene), chlorobenzene, and mixtures thereof. Particularly preferred is toluene as aromatic solvent.
  • Preferred alkane solvents include aliphatic hydrocarbons such as pentane, hexane, heptane, cyclohexane, petroleum ether, or mixtures thereof, and halogenated hydrocarbons such as methylene chloride, chloroform, or mixtures thereof.
  • a particularly preferred alkane solvent is heptane.
  • Preferred ether solvents are open-chained and cyclic ethers, in particular diethyl ether, methyl- tert-butyl-ether (MTBE), 2-methoxy-2-methylbutane, cyclopentylmethylether, 1 ,4-dioxane, tetra- hydrofuran (THF), 2-methyltetrahydrofuran (CH3-THF), or mixtures thereof.
  • Preferred ether solvents are selected from tetrahydrofuran (THF), 2-methyltetrahydrofuran (CH3-THF), methyl-tert- butyl-ether (MTBE), and mixtures thereof.
  • a particularly preferred ether solvent is MTBE.
  • Preferred ester solvents include carboxylic esters such as ethyl acetate or butyl acetate.
  • aprotic solvents include acetone, acetonitrile and dimethylformamide.
  • the aprotic solvent is selected is selected from toluene (C6H5-CH3), xylene (ortho-xylene, meta-xylene or para-xylene), chlorobenzene (MCB), heptane, tetrahydrofuran (THF), 2-methyltetrahydrofuran (CH 3 -THF), methyl-tert-butyl-ether (MTBE), 1 ,4-dioxane, ethyl acetate (EtOAc), butyl acetate, acetone, acetonitrile, and mixtures thereof.
  • toluene C6H5-CH3
  • xylene ortho-xylene, meta-xylene or para-xylene
  • MBB chlorobenzene
  • heptane heptane
  • THF tetrahydrofuran
  • CH 3 -THF 2-methyltetrahydrofuran
  • MTBE methyl
  • the aprotic solvent is an optional component of the reaction mixture, and may thus be present or not present in the reaction mixture, wherein the pyrazole precursor IV is provided for the cyclization reaction.
  • the aprotic solvent if present, is the solvent, wherein the pyrazole precursor has been prepared. If the solvent is not removed after the preparation of the pyrazole precursor, the cyclization reaction can also be performed in the presence of the aprotic solvent, although it is not essential that the aprotic solvent is present in the reaction mixture. However, the presence of a protic solvent is required according to the invention.
  • reaction mixtures according to combinations D-1 to D-42 as defined above may according to one embodiment further comprise an aprotic solvent as component (d), which may e.g. be C6H5-CH3, MTBE, or EtOAc.
  • aprotic solvent as component (d) which may e.g. be C6H5-CH3, MTBE, or EtOAc.
  • the preferred reaction mixtures not further comprise an aprotic solvent as component (d).
  • the particularly preferred combinations D-1 to D-42 may not further comprise an aprotic solvent as component (d).
  • the pyrazole precursor IV is provided in a reaction mixture comprising components (a), (b), (c), and optionally (d) as defined above. Suitable amounts of the components (a) and (b) have been defined above. A skilled person knows suitable amounts of the solvent for the reaction.
  • one strategy is to work at rather low concentrations. This applies in particular if the process is performed batch wise.
  • Other strategies for improving the selectivity include modifying the acid, e.g. using a weaker acid, or dosing of the acid.
  • a water scavenger for example molecular sieves, sodium, magnesium and calcium salts (preferably sodium sulfate, magnesium sulfate, calcium chloride), trimethyl orthoformate, triethyl orthoformate, phosphoryl chloride, phosphorus pentachloride, oleum, acetic anhydride, alkyl acyl chlorides, benzoyl chlorides, sul- furyl chlorides, carbodiimides, aluminum or silcon based resins or oxides.
  • a water scavenger for example molecular sieves, sodium, magnesium and calcium salts (preferably sodium sulfate, magnesium sulfate, calcium chloride), trimethyl orthoformate, triethyl orthoformate, phosphoryl chloride, phosphorus pentachloride, oleum, acetic anhydride, alkyl acyl chlorides, benzoyl chlorides, sul- furyl chlorides, carbodiimides, aluminum or silcon
  • the compound of formula IV is present in the reaction mixture in an amount of at most 50 wt.-%, preferably at most 20 wt.-%, based on the total weight of the reaction mixture.
  • the preferred concentration of compound IV in the reaction mixture is from 5 to 20 wt.-%. In a more preferred embodiment, the compound of formula IV is therefore present in the reaction mixture in an amount of at most 10 wt.-%, based on the total weight of the reaction mixture.
  • Preferred amount ranges of the compound of formula IV in the reaction mixture are from 0.1 to 20 wt.-%, preferably 1 to 10 wt.-%, more preferably 1 to 5 wt.-% based on the total weight of the reaction mixture.
  • the compound of formula IV may be present in the reaction mixture in an amount of 5 ⁇ 1 wt.-%.
  • a lower concentration generally favours the formation of the py- razole V.
  • the compound of formula IV is in a solution dosed into the reaction mixture.
  • concentration of of IV in the solvent is not critical, an upper limit is given only by the solubility of IV in the solvent, it is usually 20-50 wt-%.
  • concentration of unreacted IV in the reaction mixture is very low.
  • concentration of the pyrazole V in the reaction mixture is usually in the range of 5 to 20 wt- %, preferably 10 to 15 wt-%.
  • concentrations may be higher in a continuous or semi-con- tinuous process.
  • concentrations of more than 10 wt.-% or more than 20 wt.-%, e.g. from 20 to 80 wt.-% or from 20 to 50 wt.-%, based on the total weight of the reaction mixture may be used.
  • the pyrazole precursor IV being provided in the reaction mixture as defined above is reacted with hydrogen according to the invention, which results in the formation of the pyrazole compounds of formula V via a cyclization reaction.
  • the hydrogen is typically provided in gaseous form.
  • Suitable reaction vessels for such hydro- genation reactions are known to a skilled person. Further details in this regard are provided further below.
  • the reaction with hydrogen is performed at a temperature of at least -20°C, preferably of at least 0°C. In a preferred embodiment, the reaction with hydrogen is performed at a temperature of from - 20°C to 40 °C, of from 0 to 40°C, e.g. in the range of 5 to 15°C, at room temperature (i.e. 20-25 °C) or at a temperature from 25 °C to 35 °C. In one embodiment of the invention, the hydrogen is provided with a pressure of at least 1 bar (100 kPa).
  • the hydrogen is provided with a pressure of at least 5 bar (500 kPa).
  • the hydrogen pressure depends on the reaction vessels. If the process is performed as a batch process, the hydrogen pressure preferably does not exceed 100 bar (10000 kbar), while in a continuous process, pressures up to 500 bar (50000 kPa) can be suitable. A higher pressure usually increases the selectivity of the reaction, and suppresses the formation of by-products. For technical reasons however, the reaction is preferably run at a pressure of from 5 to 80 bar, particularly from 5 to 20 bar.
  • the process is performed
  • hydrogen is provided with a pressure of 5 to 80 bar (500 to 8000 kPa), preferably 5 to 50 bar (500 to 5000 kPa), particularly from 5 to 20 bar (500 to 2000 kPa), e.g. 10 bar (1000 kPa).; or
  • the process is performed as a semi-batch process with a pressure of 5 to 500 bar (500 to 50000 kPa), preferably from 10 to 250 bar (1000 to 25000 kPa), particularly from 5 to 25 bar (5000 to 2500 kPa); e.g. 10 to 20 bar (1000 to 2000 kPa).
  • a preferred pressure range is from 10 to 500 bar (1000 to 50000 kPa), preferably from 100 to 500 bar (10000 to 50000 kPa).
  • reaction step (c) of the process of the invention may be operated in batch, semi-batch or continuous mode using a conventional stirred tank reactor.
  • Alternative continuous multiphase catalytic reactors can be also used, where the catalyst can be fixed (trickle bed or packed column technology) or mobile (slurry bubble column, jet/loop reactor or air lift reactor).
  • E. H. Stitt Chemical Engineering Journal, 2002, 90, 47-60.
  • New continuous flow reactors can be also employed using a slurry (falling film or corning reactors) as described by M. Irfan et al.
  • the process of the invention may further comprise reaction steps (a) and (b) as defined above for the preparation of the pyrazole precursors IV. These reaction steps of the process of the present invention are described hereinafter.
  • reaction steps (a) and (b) of the process of the invention are to be understood as preferred alone or in combination with each other and in combination with the preferences regarding process step (c).
  • the process of the invention in a preferred embod- iment further comprises the step (b) of preparing the hydrazone substituted ⁇ , ⁇ -unsaturated car- bonyl compound of formula IV
  • X is halogen, OH, Ci-Cio-alkoxy, C3-Cio-cycloalkoxy, Ci-Cio-alkyl-C(0)0-, Ci-Cio-alkyl- S(0) 2 0-, Ci-Cio-haloalkyl-S(0) 2 0-, phenyl-S(0) 2 0-, tolyl-S(0) 2 0-, (Ci-Cio-alkyloxy) 2 P(0)0-, Ci- Cio-alkylthio, C3-Cio-cycloalkylthio, Ci-Cio-alkyl-C(0)S-, NH 2 , Ci-Cio-alkylamino, Ci-Cio-dialkyla- mino, morpholino, N-methylpiperazino, or aza-C3-Cio-cycloalkyl; and is preferably OCH 2 CH3; and R 1 , R 2 , R 3 , R 4 and R 5 are as defined above.
  • X is halogen, Ci-C4-alkoxy, Ci-C4-dialkylamino, morpholino, N-methylpiperazino, or aza-Cs-Ce-cycloalkyl.
  • X is halogen, preferably chlorine.
  • X is Ci-C4-dialkylamino or Ci-C4-alkoxy.
  • X is Ci-C4-dialkylamino, preferably dimethylamino or diethyl- amino.
  • X is Ci-C4-alkoxy, in particular Ci-C 2 -alkoxy, prefera- bly OCH 2 CH 3 .
  • R 1 , R 2 , and R 3 correspond to a combination according to any one of Tables 1 to 9, and X is N(CH3)2. Furthermore, it is preferred that in the compounds of formula III, R 1 , R 2 , and R 3 correspond to a combination according to any one of Tables 1 to 9, and X is N(CH2CH3)2.
  • the reaction can be performed under reaction conditions known in the art.
  • the reaction can be carried out by a process, wherein the compound of formula II is reacted with a compound of formula III either in the absence of a solvent or in an organic solvent, wherein a basic catalyst may optionally be present.
  • Suitable reaction temperatures for the reaction are in the range of from -20°C to 50°C, preferably from 15°C to 40°C, more preferably from 20 to 25°C. It is typically preferred that the compounds of formulae II and III are mixed with each other at temperatures below 0°C, preferably about -20°C, and that the mixture is then allowed to warm to a reaction temperature defined above.
  • the overall reaction times may vary in a broad range, e.g. from 1 hour to 1 day, preferably from 3 to 12 hours.
  • the compound of formula II may be provided as the crude product of step (a), i.e. without per- forming any purification steps prior to step (b), or as part of the reaction mixture obtained in step (a), to which the compound of formula III may then be added.
  • the compound of formula III is commercially available or can be prepared by methods known in the art.
  • the compound of formula III is used in amounts in the range of from 0.1 to 10.0 mol, preferably from 0.8 to 1 .5 mol, more preferably from 0.9 to 1.3 mol per mol of the compound of formula II.
  • the reaction can easily be performed without having to use a catalyst.
  • the reaction may also be performed in the presence of a basic catalyst.
  • Preferred basic catalysts include BaO, CaO, MgC0 3 , CaC0 3 , Na 2 C0 3 , K 2 C0 3 and NEt 3 . If a basic catalyst is used, amounts in the range of from 0.01 to 2.0 mol, preferably from 1 .0 to 2.0 mol, per mol of the compound of formula II are preferred.
  • the solvent is an organic solvent, either an aprotic or a protic solvent or a mixture thereof.
  • process step (b) of the invention is performed in an aprotic solvent.
  • aprotic solvents have already been defined above and include aromatic solvents, al- kane solvents, ether solvents, ester solvents, and mixtures thereof, especially toluene, xylene (ortho-xylene, meta-xylene or para-xylene), chlorobenzene (MCB), heptane, tetrahydrofuran (THF), 2-methyltetrahydrofuran (CH 3 -THF), ethyl acetate, butyl acetate, and mixtures thereof.
  • Particularly preferred aprotic solvents in connection with step (b) of the process of the invention are the ether solvents as defined above, preferably THF, CH 3 -THF, and MTBE, in particular MTBE, and the aromatic solvents as defined above, in particular toluene.
  • process step (b) of the invention is performed in a protic solvent.
  • Protic solvents have already been defined above.
  • Preferred protic solvents in connection with step (b) of the process of the invention are Ci-C4-alkanols, in particular ethanol.
  • process step (b) may also be performed in a mixture of a protic solvent and an aprotic solvent, for example in a mixture of an ether solvent or an aromatic solvent and a C1-C4- alkanol, preferably in a mixture of MTBE and ethanol or in a mixture of toluene and ethanol.
  • step (b) in a protic solvent or in a solvent mixture comprising a protic solvent and an aprotic solvent provides the advantage that a composition is obtained, which can directly be used for the subsequent cyclization reaction according to step (c) of the process of the invention by simply adding components (a) and (b) of the above defined reaction mixture.
  • step (b) is performed in an aprotic solvent, it is required to add components (a), (b), and (c) of the above defined reaction mixture before performing the cyclization reaction. In certain situation, it can then be preferred to perform a solvent swap, i.e. to replace the aprotic solvent by the protic solvent.
  • the pyrazole precursor IV as obtained after step (b) of the pro- cess of the invention is not purified before the subsequent cyclization reaction.
  • the step of preparing the pyrazole compound of formula V and the step of preparing the compound of formula IV are performed in a one-pot procedure, wherein the compound of formula IV is subjected to the cyclization reaction without previous purification.
  • step (b) is performed, the following embodiments are preferred for step (c) of the process of the invention, if performed separately or if performed in a one-pot procedure. It is preferred that
  • step of preparing the compound of formula IV is performed in a protic solvent or in a solvent mixture comprising a protic solvent and an aprotic solvent, the step of preparing the pyrazole compound of formula V is performed in the same solvent or solvent mixture as used in the step of preparing the compound of formula IV; or
  • step of preparing the compound of formula IV is performed in an aprotic solvent, the aprotic solvent is replaced by a protic solvent, or a protic solvent is added before the step of preparing the pyrazole compound of formula V.
  • the option of performing a solvent swap can be preferred, wherein at least 90 wt.-%, preferably at least 99 wt.-% of the aprotic solvent are removed and a protic solvent is added to replace the removed aprotic solvent.
  • a solvent swap may be performed, wherein an ether solvent is replaced by a Ci-C4-alkanol, or preferably MTBE is replaced by ethanol.
  • Step (a) of the process of the invention covers the preparation of the hydrazone compounds of formula I I , wherein hydrazine monohydrate or a solution of hydrazine, is reacted with a compound of formula I either in the absence of a solvent or in an aqueous or organic solvent, wherein a basic or an acidic catalyst may optionally be present.
  • reaction is conducted in the absence of a solvent.
  • reaction is conducted in the absence of a catalyst.
  • Suitable reaction temperatures for the reaction are in the range of from 0°C to 80°C, preferably from 15°C to 50°C, more preferably from 20 to 25°C. In certain situations, it can be preferred to start at a lower temperature of from 20 to 25 °C for about 1 hour and then heat the reaction mixture to a higher temperature of from 50 to 80°C. In other situations, it can be preferred to start at a medium temperature of from 30 to 50°C for about 1 hour and then stir the reaction mixture at a temperature of from 20 to 25°C.
  • the overall reaction times may vary in a broad range, e.g. from 1 hour to 3 days. It is therefore preferred that the reaction is monitored by analytical methods and stopped after complete conversion of the compound of formula I into formula II.
  • the compound of formula I is commercially available or can be prepared by methods known in the art.
  • hydrazine is preferably provided in the form of the monohydrate or in the form of a solution of said monohydrate in water.
  • concentrations for aqueous hydrazine monohydrate solutions are in the range of 45 to 100 % by weight, preferably 60 to 100 % by weight, e.g., 80 to 100 % or 70 to 90 % by weight of hydrazine monohydrate based on the total weight of the solution.
  • hydrazine is used as 100 % hydrazine monohydrate or as an aqueous solution of hydrazine monohydrate with a concentration of about 80 wt.-% of hydrazine monohydrate based on the total weight of the solution.
  • hydrazine is used at least in stochiometric amounts.
  • hydrazine is used in amounts in the range of from 1 .0 to 10.0 mol, preferably from 1.0 to 2.0 mol, more preferably from 1.0 to 1 .5 mol, per mol of the compound of formula I.
  • the compound of formula I is added to hydrazine monohydrate or a solution thereof and not vice versa, so that it is avoided that an excess of the compound of formula I compared to hydrazine is present in the reaction mixture upon mixing the two components.
  • the solvent is an organic solvent, either an aprotic or a protic solvent or a mixture thereof.
  • Suitable aprotic solvents include aromatic solvents, ethers, or mixtures thereof.
  • Preferred aromatic solvents are e.g. benzene, toluene, xylene (ortho-xy- lene, meta-xylene or para-xylene), mesitylene, chlorobenzene, 1 ,2-dichlorobenzene, 1 ,3-dichlo- robenzene, 1 ,4-dichlorobenzene, or mixtures thereof.
  • Preferred ethers are open-chained and cyclic ethers, in particular diethyl ether, methyl-tert-butyl-ether (MTBE), 2-methoxy-2-methyl- butane, cyclopentylmethylether, 1 ,4-dioxane, tetrahydrofuran, 2-methyltetrahydrofuran, or mixtures thereof.
  • Protic solvents are typically preferred as solvents.
  • Suitable protic solvents are Ci- C4-alkanols such as methanol, ethanol, propanol and isopropanol, C2-C4-alkandiols, such as ethylene glycol or propylene glycol, and ether alkanols such as diethylene glycol, and mixtures thereof.
  • Ci-C4-alkanols e.g. methanol, ethanol, isopropanol, butanol, or mixtures thereof, in particular ethanol.
  • the reaction may also be performed in the presence of an acidic or basic catalyst.
  • Preferred acid catalysts include HCI in H 2 0, HCI in MeOH, HCI in dioxane; H 2 S0 4 , H 3 P0 4 and salts of H2SO4 and H3PO4; aromatic sulfonic acids such as toluene sulfonic acid; alkylsulfonic acids, such as methyl sulfonic acid; aromatic carboxylic acids such as benzoic acid; alkylcarboxylic ac- ids such as acetic acid; salts of rare earth metals; and Lewis acids such as BF 3 , BF 3 x OEt 2 , BF 3 x SMe2, TiCU, Ti(OiPr) 4 .
  • a preferred acid catalyst is acetic acid.
  • Preferred basic catalysts include BaO, CaO, MgCOs, CaCOs, Na 2 C0 3 , K2CO3 and NEt 3 .
  • a preferred basic catalyst is BaO.
  • the acidic or basic catalyst is preferably used in amounts in the range of from 0.001 to 10 mol, preferably from 0.01 to 0.5 mol, more preferably from 0.02 to 0.3 mol, per mol of the compound of formula I .
  • amounts in the range of from 0.05 to 0.2 mol per mol of the compound of formula I can be preferred.
  • amounts in the range of from 0.15 to 0.25 or from 0.2 to 0.3 mol per mol of the compound of formula I can be preferred.
  • the compounds of formula I I are not purified before the preparation of the compounds of formula IV according to step (b) of the process of the invention.
  • the step of preparing the pyrazole precursors IV and the step of preparing the compound of formula I I are performed in a one-pot procedure, wherein the compound of formula I I is used for reaction step (b) without previous purification.
  • process steps (a), (b), and (c) are performed as a one- pot procedure.
  • the process of the invention may further comprise reaction steps (d), (e) and (f) for further transformations of the pyrazole compounds V, which are obtained according to step (c) of the process of the invention.
  • reaction conditions for step (d) of the process of the invention are as follows.
  • step (d) a compound of formula Va or Vb is converted into a compound of formula Vc.
  • said reaction may be understood as a hydrolysis reaction because an ester or a nitrile is hydrolyzed to give the free acid.
  • other conversion reactions of esters or nitriles into the free acids such as the conversion of tert-butyl esters into the free acids by the addition of trifluoroacetic acid, are also covered by the invention.
  • the reaction may be carried out by a process, wherein the compound of formula Va or Vb is reacted with water e.g. in the presence of a base or in the presence of an acid, or by a process, wherein the compound of formula Va or Vb is reacted with a water soluble base, preferably an oxo-base, in an aqueous solvent, or by a process, wherein the compound of formula Va or Vb is reacted with a hydroxide in a protic aqueous or organic solvent.
  • Such hydrolysis reactions can be performed according to procedures known in the art.
  • step (d) is performed by dissolving a compound of formula Va in a protic solvent, either an aqueous solvent such as water or in a protic organic solvent, a such as a Ci-C4-alkanol, e.g. methanol, ethanol or isopropanol, and adding a hydroxide.
  • a protic solvent either an aqueous solvent such as water or in a protic organic solvent, a such as a Ci-C4-alkanol, e.g. methanol, ethanol or isopropanol, and adding a hydroxide.
  • Suitable hydroxides include alkali metal hydroxides such as lithium, sodium or potassium hydroxide, and mixtures thereof. Sodium hydroxide is particularly preferred.
  • sodium hydroxide is used in amounts of from 1 to 10 mol, preferably from 2.0 to 6.0 mol, e.g. 2.0 to 3.0 mol or 5.0 to 6.0 mol, per mol of the compound of formula Va.
  • Suitable reaction temperatures may vary from 20 to 100°C, e.g. from 20 to 25°C or from 50 to 100°C.
  • the reaction times may vary from 1 hour to 2 days, e.g. from 1 to 3 hours or from 12 hours to 24 hours or from 1 to 2 days.
  • the conversion of compounds of formula Va into compounds of formula Vc can be enhanced, and complete conversion can more easily be ensured, if the alcohol, which is formed upon hydrolysis of the compounds of formula Va, is removed from the reaction mixture, e.g. by distillation.
  • the resulting compounds of formula Vc can be purified by methods known in the art, e.g. by crystallization under suitable pH conditions.
  • reaction conditions for steps (e) and (f) of the process are as follows.
  • step (e) the compound of formula Vc is activated by converting it into the activated acid derivative of formula VI.
  • Suitable peptide coupling reagents which may be used for introducing the leaving group X 1 of the compounds of formula VI starting from compounds of formula V, are described by Han et al. in Tetrahedron 60 (2004) 2447-2467.
  • N,N'-bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-CI) and 0-(7-azabenzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophos- phate (HATU) are preferred according to the present invention.
  • the compound of formula VI may either be directly converted into a compound of formula VIII or isolated. It is preferred, however, that the compound of formula VI is directly converted into the compound of formula VIII.
  • reaction step (c) i.e. the preparation of the pyrazole compounds V starting from the pyrazole precursors IV.
  • compositions which can be used as starting materials for the preparation of the above defined reaction mixture comprising the pyrazole precursor IV, which is then subjected to the hydrogen induced cyclization reaction in step (c) of the process of the invention.
  • Figure 1 shows a preferred scheme for performing reaction step (c) of the process of the invention by - providing a first composition (referred to as “IV + EtOH (c)”) comprising the pyrazole precursor IV and ethanol, i.e. component (c) of the desired reaction mixture, and a second composition (referred to as “(b) + EtOH (c)”) comprising an acid selected from Bransted acids, ammonium salts of Bransted acids, and Lewis acids, i.e. component (b) of the desired reaction mix- ture, and ethanol, i.e. component (c) of the desired reaction mixture, and
  • compositions with Pt/C as hydrogenation catalyst, i.e. component (a), in a suitable reaction vessel to form the desired reaction mixture for the cyclization reaction of the pyrazole precursor IV, and
  • reaction mixture comprising the pyrazole precursor IV to hydrogen at a pres- sure of 10 to 50 bar at a temperature of from 0 to 40 °C,
  • the present invention relates to a composition
  • a composition comprising
  • R 1 is C(0)OCH 2 CH 3 ;
  • R 2 is CH 3 ;
  • R 3 is H;
  • R 4 is CH(CH 3 ) 2 ;
  • R 5 is CH 3 , being compound IV.1 and
  • an acid selected from Bransted acids, ammonium salts of Br0nsted acids, and Lewis acids, and
  • the present invention relates to a composition A comprising (1 ) compound IV.1 , and
  • the hydrogenation catalyst is Pt/C, or PtC>2.
  • the hydrogenation catalyst is Pt/C.
  • This composition may be combined with components (b) and (c) of the reaction mixture as defined above to perform the cyclization reaction in the presence of hydrogen according to step (c) of the process of the invention.
  • the present invention relates to a composition B comprising (1 ) compound IV.1 , and
  • the acid is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • a Bransted acid selected from trifluoroacetic acid (TFA), phosphoric acid (H3PO4) and sulfuric acid (H2SO4),
  • (b3) a Lewis acid selected from BF 3 * OEt 2 , FeCI 3 , TiCU, and AICI3.
  • the acid is TFA.
  • the acid is H2SO4.
  • the acid is MSA * pyr.
  • the acid is BF3*OEt2.
  • the acid is FeC .
  • the acid is TiCU.
  • the acid is AICI3.
  • composition may be combined with components (a) and (c) of the reaction mixture as defined above to perform the cyclization reaction in the presence of hydrogen according to step (c) of the process of the invention.
  • the present invention relates to a composition C comprising (1 ) compound IV.1 , and
  • composition may be combined with components (a) and (b) of the reaction mixture as defined above to perform the cyclization reaction in the presence of hydrogen according to step (c) of the process of the invention.
  • composition C is particularly advantageous for the purpose of the present invention, not only because ethanol is a particularly preferred solvent for reaction step (c) of the invention, but also because the reaction mixture, wherein the compound of formula IV is provided, is preferably prepared by mixing composition C (comprising the pyrazole precursor IV and component (c)) with component (b), optionally provided in an additional amount of solvent, and then adding the hydrogenation catalyst (a).
  • reaction mixture comprising the pyrazole precursor IV and component (c)
  • component (b) optionally provided in an additional amount of solvent
  • the present invention relates to a composition D comprising
  • composition D may be combined with, i.e. slowly dosed to the reaction mixture which comprises components (a), (b) and (c) to perform the cyclization reaction in the presence of hydrogen according to step (c) of the process of the invention.
  • the reaction mixture comprises
  • composition D is particularly advantageous for the purpose of the present invention, not only because methanol is a particularly preferred solvent for the semi- batch process reaction step (c) of the invention, but also because the reaction mixture, to which the solution of compound of formula IV is dosed to, allows a highly selective reaction of com- pound IV to the pyrazole V.
  • compositions may also comprise combinations of components (a), (b), and (c).
  • the present invention therefore relates to a composition com- prising
  • the present invention relates to a composition
  • a composition comprising
  • the detection of the compounds can be done by coupled High Performance Liquid
  • Example 2 Screening experiment To a suspension of Pt/C (0.7 g) in 31 g MeOH 1.8 g (0.5 equiv )H 2 S04 were added. The reaction vessel was pressurized with hydrogen to 15 bar and cooled to 10°C. To the reaction mixuture was dosed a solution of 9 g ethyl 2-[[2-(2,2-dimethyl-1-methyl-ethylidene)hydra- zino]methylene]-3-oxo-butanoate (0.04 mol, compound IV.1 ) in 20 g MeOH over 240 min using an HPLC pump. The reaction mixture was stirred for an additional hour following the dosing.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne un procédé catalytique permettant de préparer des pyrazoles, ledit procédé comprenant l'étape consistant à cycliser des composés carbonyle α,β-insaturés à substitution hydrazone en les faisant réagir avec de l'hydrogène dans un mélange réactionnel comprenant, comme composants, (a) un catalyseur d'hydrogénation, (b) un acide choisi parmi les acides de Brønsted, les sels d'ammonium d'acides de Brønsted et les acides de Lewis, (c) un solvant protique et éventuellement (d) un solvant aprotique.
PCT/EP2017/051524 2016-02-02 2017-01-25 Procédé d'hydrogénation catalytique pour la préparation de pyrazoles WO2017133942A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
MX2018009453A MX2018009453A (es) 2016-02-02 2017-01-25 Proceso de hidrogenacion catalitico para preparar pirazoles.
AU2017216082A AU2017216082B2 (en) 2016-02-02 2017-01-25 Catalytic hydrogenation process for preparing pyrazoles
PL17701485T PL3411360T3 (pl) 2016-02-02 2017-01-25 Sposób katalitycznego uwodorniania dla wytwarzania pirazoli
CN201780009304.6A CN108699003B (zh) 2016-02-02 2017-01-25 制备吡唑类的催化氢化方法
JP2018558485A JP6900400B2 (ja) 2016-02-02 2017-01-25 ピラゾールを調製する接触水素化方法
DK17701485.9T DK3411360T3 (da) 2016-02-02 2017-01-25 Fremgangsmåde til katalytisk hydrogenering til fremstilling af pyrazoler
ES17701485T ES2795874T3 (es) 2016-02-02 2017-01-25 Proceso de hidrogenación catalítica para preparar pirazoles
CA3010561A CA3010561C (fr) 2016-02-02 2017-01-25 Procede d'hydrogenation catalytique pour la preparation de pyrazoles
RU2018130339A RU2733958C2 (ru) 2016-02-02 2017-01-25 Способ каталитического гидрирования для получения пиразолов
KR1020187025347A KR102651666B1 (ko) 2016-02-02 2017-01-25 피라졸을 제조하기 위한 촉매적 수소화 방법
US16/074,537 US10975036B2 (en) 2016-02-02 2017-01-25 Catalytic hydrogenation process for preparing pyrazoles
BR112018014357A BR112018014357B8 (pt) 2016-02-02 2017-01-25 Processo para a preparação de um composto de pirazol e composição
EP17701485.9A EP3411360B1 (fr) 2016-02-02 2017-01-25 Procédé d'hydrogenation catalytique pour l'obtention de composés à base de cycle pyrazole
IL260375A IL260375B (en) 2016-02-02 2018-07-02 Catalytic hydrogenation process for the preparation of pyrazoles
CONC2018/0008428A CO2018008428A2 (es) 2016-02-02 2018-08-10 Proceso de hidrogenación catalítico para preparar pirazoles
ZA201805742A ZA201805742B (en) 2016-02-02 2018-08-28 Catalytic hydrogenation process for preparing pyrazoles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16153833.5 2016-02-02
EP16153833 2016-02-02

Publications (1)

Publication Number Publication Date
WO2017133942A1 true WO2017133942A1 (fr) 2017-08-10

Family

ID=55304873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/051524 WO2017133942A1 (fr) 2016-02-02 2017-01-25 Procédé d'hydrogénation catalytique pour la préparation de pyrazoles

Country Status (20)

Country Link
US (1) US10975036B2 (fr)
EP (1) EP3411360B1 (fr)
JP (1) JP6900400B2 (fr)
KR (1) KR102651666B1 (fr)
CN (1) CN108699003B (fr)
AU (1) AU2017216082B2 (fr)
BR (1) BR112018014357B8 (fr)
CA (1) CA3010561C (fr)
CL (1) CL2018002075A1 (fr)
CO (1) CO2018008428A2 (fr)
DK (1) DK3411360T3 (fr)
ES (1) ES2795874T3 (fr)
IL (1) IL260375B (fr)
MX (1) MX2018009453A (fr)
PE (1) PE20181539A1 (fr)
PL (1) PL3411360T3 (fr)
PT (1) PT3411360T (fr)
RU (1) RU2733958C2 (fr)
WO (1) WO2017133942A1 (fr)
ZA (1) ZA201805742B (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10344008B2 (en) 2015-05-08 2019-07-09 BASF Agro B.V. Process for the preparation of terpinolene epoxide
US10414733B2 (en) 2014-07-31 2019-09-17 Basf Se Process for preparing pyrazoles
US10526264B2 (en) 2016-07-07 2020-01-07 Basf Se Oxy-cope rearrangement for the manufacture of insecticidal cyclopentene compounds
US10538493B2 (en) 2016-11-17 2020-01-21 Basf Se Process for the purification of 1-(4-chlorophenyl)pyrazol-3-ol
US10538470B2 (en) 2015-05-08 2020-01-21 BASF Agro B.V. Process for the preparation of limonene-4-ol
US10584102B2 (en) 2015-05-11 2020-03-10 Basf Se Process for preparing 4-amino-pyridazines
US10640477B2 (en) 2016-06-15 2020-05-05 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
US10961213B2 (en) 2017-01-25 2021-03-30 Basf Se Process for preparation of benzylic amides
US10961226B2 (en) 2016-11-04 2021-03-30 Basf Se Process for purification of pyrazolpyridazines
US11072593B2 (en) 2016-06-15 2021-07-27 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
US11261145B2 (en) 2017-03-20 2022-03-01 Basf Se Process for preparing bromotrichloromethane
US11358922B2 (en) 2017-11-02 2022-06-14 Basf Se Process for preparing 4-chlorobenzyl propargyl ether

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007326784A (ja) 2006-06-06 2007-12-20 Sagami Chem Res Center １−置換−５−フルオロアルキルピラゾール−４−カルボン酸エステルの製造方法
WO2009027393A2 (fr) 2007-08-27 2009-03-05 Basf Se Composés de pyrazole permettant de lutter contre les nuisibles invertébrés
WO2010034737A1 (fr) 2008-09-24 2010-04-01 Basf Se Composés de pyrazole pour la lutte contre des parasites invertébrés
WO2010034738A2 (fr) 2008-09-24 2010-04-01 Basf Se Composés pyrazoliques utilisables dans la lutte contre les invertébrés nuisibles
WO2010112177A1 (fr) 2009-04-03 2010-10-07 Bayer Cropscience Aktiengesellschaft Amines pyridines et –pyridazines acylées en tant qu'insecticides
WO2010142628A1 (fr) 2009-06-08 2010-12-16 Merck Serono S.A. Dérivés pyrazoles oxadiazoles en tant qu'agonistes de s1p1
WO2012019015A2 (fr) 2010-08-04 2012-02-09 Deciphera Pharmaceuticals, Llc Procédés et compositions pour le traitement de maladies myéloprolifératives et d'autres maladies prolifératives
US20130324547A1 (en) * 2012-05-31 2013-12-05 Roch Boivin Tetrahydropyrazolopyrimidine compounds
EP2671873A1 (fr) 2012-06-06 2013-12-11 Solvay Sa Procédé de diagnostic de moteur à combustion interne par l'analyse de ses gaz d'échappement et dispositif pour sa mise en ýuvre
WO2016016369A1 (fr) * 2014-07-31 2016-02-04 Basf Se Procédé de préparation de pyrazoles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143293B2 (en) * 2007-04-20 2012-03-27 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
WO2009068652A1 (fr) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation Pyridines 2, 6-disubstituées et pyrimidines 2, 4-disubstituées en tant qu'activateurs de guanylate cyclase soluble
CN102015654B (zh) * 2008-05-05 2014-03-12 巴斯夫欧洲公司 制备1，3，4-取代的吡唑化合物的方法
CN107334529B (zh) 2011-04-12 2020-06-09 热医学公司 用于对流体增强型消融装置使用除气流体的方法和装置
BR112013024708B1 (pt) * 2011-04-21 2018-10-09 Basf Se compostos de pirazol,composições, métodos para combater ou controlar pragas invertebradas e para proteger plantas em crescimento, processo para proteger sementes e uso dos compostos
ES2660132T3 (es) * 2012-06-20 2018-03-20 Basf Se Compuestos de pirazol plaguicidas
WO2014089364A1 (fr) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Inhibiteurs de l'histone déméthylase
PE20180327A1 (es) 2015-05-11 2018-02-13 Basf Se Proceso para preparar 4-amino-piridazinas

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007326784A (ja) 2006-06-06 2007-12-20 Sagami Chem Res Center １−置換−５−フルオロアルキルピラゾール−４−カルボン酸エステルの製造方法
WO2009027393A2 (fr) 2007-08-27 2009-03-05 Basf Se Composés de pyrazole permettant de lutter contre les nuisibles invertébrés
WO2010034737A1 (fr) 2008-09-24 2010-04-01 Basf Se Composés de pyrazole pour la lutte contre des parasites invertébrés
WO2010034738A2 (fr) 2008-09-24 2010-04-01 Basf Se Composés pyrazoliques utilisables dans la lutte contre les invertébrés nuisibles
WO2010112177A1 (fr) 2009-04-03 2010-10-07 Bayer Cropscience Aktiengesellschaft Amines pyridines et –pyridazines acylées en tant qu'insecticides
WO2010142628A1 (fr) 2009-06-08 2010-12-16 Merck Serono S.A. Dérivés pyrazoles oxadiazoles en tant qu'agonistes de s1p1
WO2012019015A2 (fr) 2010-08-04 2012-02-09 Deciphera Pharmaceuticals, Llc Procédés et compositions pour le traitement de maladies myéloprolifératives et d'autres maladies prolifératives
US20130324547A1 (en) * 2012-05-31 2013-12-05 Roch Boivin Tetrahydropyrazolopyrimidine compounds
EP2671873A1 (fr) 2012-06-06 2013-12-11 Solvay Sa Procédé de diagnostic de moteur à combustion interne par l'analyse de ses gaz d'échappement et dispositif pour sa mise en ýuvre
WO2016016369A1 (fr) * 2014-07-31 2016-02-04 Basf Se Procédé de préparation de pyrazoles

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Liebigs Analen der Chemie", 1985, pages: 794
ALTENBACH R J ET AL: "Synthesis, Potency, and in vivo Profiles of Quinoline containing Histamine H3 Receptor Inverse Agonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 50, no. 22, 1 November 2007 (2007-11-01), pages 5439 - 5448, XP002488452, ISSN: 0022-2623, [retrieved on 20071006], DOI: 10.1021/JM0705051 *
E. H. STITT, CHEMICAL ENGINEERING JOURNAL, vol. 90, 2002, pages 47 - 60
GLORIUS ET AL., ANGEW. CHEM. INT. ED., 2010, pages 7790
GREEN CHEM., vol. 14, 2012, pages 2193
HAN ET AL., TETRAHEDRON, vol. 60, 2004, pages 2447 - 2467
HETEROCYCLES, 2000, pages 2775
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1985, pages 1109
JOURNAL OF ORGANOMETALLIC CHEMISTRY, vol. 370, 1989, pages 17 - 31
M. IRFAN ET AL., CHEMSUSCHEM, vol. 4, 2011, pages 300 - 316
R. MUNIRATHINAM ET AL., ADV. SYNTH. CATAL., vol. 357, 2015, pages 1093 - 1123
S. I. YAKIMOVICH ET AL: "Reactions of 3-ethoxymethylidenepentane-2,4-dione and ethyl 2-ethoxymethylidene-3-oxobutanoate with benzohydrazide", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, vol. 44, no. 4, 1 April 2008 (2008-04-01), pages 621 - 623, XP055148546, ISSN: 1070-4280, DOI: 10.1134/S1070428008040271 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414733B2 (en) 2014-07-31 2019-09-17 Basf Se Process for preparing pyrazoles
US10513498B2 (en) 2014-07-31 2019-12-24 Basf Se Process for preparing pyrazoles
US10344008B2 (en) 2015-05-08 2019-07-09 BASF Agro B.V. Process for the preparation of terpinolene epoxide
US10538470B2 (en) 2015-05-08 2020-01-21 BASF Agro B.V. Process for the preparation of limonene-4-ol
US11046656B2 (en) 2015-05-11 2021-06-29 Basf Se Process for preparing 4-amino-pyridazines
US10584102B2 (en) 2015-05-11 2020-03-10 Basf Se Process for preparing 4-amino-pyridazines
US11072593B2 (en) 2016-06-15 2021-07-27 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
US10640477B2 (en) 2016-06-15 2020-05-05 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
US10526264B2 (en) 2016-07-07 2020-01-07 Basf Se Oxy-cope rearrangement for the manufacture of insecticidal cyclopentene compounds
US10961226B2 (en) 2016-11-04 2021-03-30 Basf Se Process for purification of pyrazolpyridazines
US10538493B2 (en) 2016-11-17 2020-01-21 Basf Se Process for the purification of 1-(4-chlorophenyl)pyrazol-3-ol
US10961213B2 (en) 2017-01-25 2021-03-30 Basf Se Process for preparation of benzylic amides
US11261145B2 (en) 2017-03-20 2022-03-01 Basf Se Process for preparing bromotrichloromethane
US11358922B2 (en) 2017-11-02 2022-06-14 Basf Se Process for preparing 4-chlorobenzyl propargyl ether

Also Published As

Publication number Publication date
AU2017216082B2 (en) 2020-12-03
MX2018009453A (es) 2018-09-21
CA3010561C (fr) 2024-04-16
EP3411360B1 (fr) 2020-03-11
EP3411360A1 (fr) 2018-12-12
RU2733958C2 (ru) 2020-10-08
DK3411360T3 (da) 2020-06-08
CA3010561A1 (fr) 2017-08-10
JP6900400B2 (ja) 2021-07-07
ES2795874T3 (es) 2020-11-25
RU2018130339A3 (fr) 2020-03-19
IL260375B (en) 2021-03-25
RU2018130339A (ru) 2020-03-04
KR20180104743A (ko) 2018-09-21
PT3411360T (pt) 2020-06-01
CN108699003A (zh) 2018-10-23
CN108699003B (zh) 2023-02-03
US10975036B2 (en) 2021-04-13
AU2017216082A1 (en) 2018-07-26
CO2018008428A2 (es) 2018-08-21
CL2018002075A1 (es) 2018-09-14
BR112018014357B8 (pt) 2022-09-06
PL3411360T3 (pl) 2020-08-24
ZA201805742B (en) 2019-11-27
JP2019504883A (ja) 2019-02-21
BR112018014357A2 (pt) 2018-12-18
US20190055200A1 (en) 2019-02-21
BR112018014357B1 (pt) 2022-08-16
KR102651666B1 (ko) 2024-03-26
PE20181539A1 (es) 2018-09-26

Similar Documents

Publication Publication Date Title
AU2017216082B2 (en) Catalytic hydrogenation process for preparing pyrazoles
AU2016260784B2 (en) Process for preparing 4-amino-pyridazines
KR102531217B1 (ko) 피라졸의 제조 방법
WO2018082964A1 (fr) Procédé de production de pyridazinyle-amides dans une synthèse one pot
JP7161275B2 (ja) ４－アミノ－ピリダジンを製造するための方法
RU2778306C1 (ru) Способ получения 4-аминопиридазинов

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17701485

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 260375

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 3010561

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018014357

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017216082

Country of ref document: AU

Date of ref document: 20170125

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018558485

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 001381-2018

Country of ref document: PE

Ref document number: MX/A/2018/009453

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187025347

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201808830

Country of ref document: UA

Ref document number: 2017701485

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017701485

Country of ref document: EP

Effective date: 20180903

ENP Entry into the national phase

Ref document number: 112018014357

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180713